65271-80-9 | 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	in stock	$35.00	$24.00
100mg	95%	in stock	$106.00	$75.00
250mg	95%	in stock	$234.00	$164.00
1g	95%	in stock	$521.00	$365.00

Description

• Catalog Number: AI54485
• Chemical Name: 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione
• CAS Number: 65271-80-9
• Molecular Formula: C22H28N4O6
• Molecular Weight: 444.4809
• MDL Number: MFCD00242942
• SMILES: OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO
• NSC Number: 279836

Computed Properties

• Complexity: 571
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 8
• Rotatable Bond Count: 12
• XLogP3: 1

Literature

• Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.

  Archives of toxicology 20180101

• ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.

  Toxicology and applied pharmacology 20171215

• Impairment of oxidative phosphorylation increases the toxicity of SYD-1 on hepatocarcinoma cells (HepG2).

  Chemico-biological interactions 20160825

• Disease modifying therapies for relapsing multiple sclerosis.

  BMJ (Clinical research ed.) 20160822

• Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.

  Archives of toxicology 20160101

• The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury.

  Toxicology 20150302

• Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20141001

• Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies.

  Journal of applied toxicology : JAT 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.

  Toxicology in vitro : an international journal published in association with BIBRA 20130301

• The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

  The Journal of pharmacology and experimental therapeutics 20130201

• A case report of acute myeloid leukemia after liver transplantation.

  Acta haematologica 20130101

• High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.

  PloS one 20130101

• Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats.

  Toxicology 20121216

• Synthesis, cytotoxicity, and cell death profile of polyaminoanthraquinones as antitumor agents.

  Chemical biology & drug design 20121201

• Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts.

  Human pathology 20121101

• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Haematologica 20121101

• Breast cancer, side population cells and ABCG2 expression.

  Cancer letters 20121001

• Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.

  Toxicological sciences : an official journal of the Society of Toxicology 20121001

• Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis.

  International immunopharmacology 20121001

• cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer.

  Biomaterials 20121001

• Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells.

  Biomaterials 20121001

• A label-free method for studying DNA sequence recognition of mitoxantrone based on resonance light-scattering technique.

  The Journal of antibiotics 20121001

• Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20121001

• Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20121001

• Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

  Placenta 20121001

• Cancer cell spheroids as a model to evaluate chemotherapy protocols.

  Cancer biology & therapy 20121001

• New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.

  Bioorganic & medicinal chemistry letters 20121001

• OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.

  Biochemical pharmacology 20120915

• Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.

  Brain research 20120914

• Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

  Neurology 20120911

• Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

  Urologic oncology 20120901

• Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.

  Cytometry. Part B, Clinical cytometry 20120901

• High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.

  Haematologica 20120901

• Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

  Haematologica 20120901

• Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone.

  Pharmaceutical research 20120901

• Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

  Anti-cancer drugs 20120901

• Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.

  British journal of haematology 20120901

• The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

  Molecular cancer therapeutics 20120901

• Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.

  Human gene therapy 20120901

• Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

  Cancer biology & therapy 20120901

• Cabazitaxel in metastatic castration-resistant prostate cancer.

  Expert review of anticancer therapy 20120901

• Drug-induced atrial fibrillation.

  Drugs 20120820

• New treatment options for patients with metastatic castration-resistant prostate cancer.

  Cancer treatment reviews 20120801

• Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.

  Xenobiotica; the fate of foreign compounds in biological systems 20120801

• New use for an old drug: inhibiting ABCG2 with sorafenib.

  Molecular cancer therapeutics 20120801

• Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.

  P & T : a peer-reviewed journal for formulary management 20120801

• Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.

  Drugs 20120730

• Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.

  Cancer research 20120715

• Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.

  Rheumatology international 20120701

• Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20120701

• Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.

  Methods (San Diego, Calif.) 20120701

• Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

  Pharmaceutical research 20120701

• Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).

  British journal of haematology 20120701

• Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

  The Lancet. Oncology 20120701

• Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.

  Journal of medicinal chemistry 20120614

• Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.

  The Journal of surgical research 20120601

• Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.

  Medical oncology (Northwood, London, England) 20120601

• Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

  Bone marrow transplantation 20120601

• [Castration-resistant prostate cancer: where are we going?].

  Actas urologicas espanolas 20120601

• Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.

  European journal of neurology 20120601

• Mimicry between mitochondrial disorder and multiple sclerosis.

  Metabolic brain disease 20120601

• Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

  Endocrine-related cancer 20120601

• A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

  The AAPS journal 20120601

• Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

  Annals of hematology 20120601

• Management of children with multiple sclerosis.

  Paediatric drugs 20120601

• Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.

  Clinical journal of oncology nursing 20120601

• Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

  Bulletin du cancer 20120601

• [Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.

  Cancer 20120515

• Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells.

  Biochemical pharmacology 20120515

• Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.

  Biochemical pharmacology 20120501

• Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120501

• Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma.

  American journal of hematology 20120501

• Spectroscopic investigations of the molecular interaction of anticancer drug mitoxantrone with non-ionic surfactant micelles.

  The Journal of pharmacy and pharmacology 20120501

• A case of blastic plasmacytoid dendritic cell neoplasm.

  Annals of dermatology 20120501

• [Percutaneous coronary intervention in a patient with acute myeloid leukemia].

  Deutsche medizinische Wochenschrift (1946) 20120501

• Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.

  Anticancer research 20120501

• Noninvasive in vivo optical assessment of blood brain barrier permeability and brain tissue drug deposition in rabbits.

  Journal of biomedical optics 20120501

• Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer.

  Korean journal of urology 20120501

• Cabazitaxel for prostate cancer: patient preparation and ongoing care.

  British journal of nursing (Mark Allen Publishing) 20120501

• Accessible high-throughput virtual screening molecular docking software for students and educators.

  PLoS computational biology 20120501

• Immunotherapies in neurologic disorders.

  The Medical clinics of North America 20120501

• A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

  Blood 20120426

• A programmable microfluidic cell array for combinatorial drug screening.

  Lab on a chip 20120424

• Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.

  Journal of medicinal chemistry 20120412

• Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.

  Journal of medicinal chemistry 20120412

• Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• Clinical spectrum of CNS aquaporin-4 autoimmunity.

  Neurology 20120410

• Coordination bonding based pH-responsive albumin nanoparticles for anticancer drug delivery.

  Dalton transactions (Cambridge, England : 2003) 20120407

• Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.

  The pharmacogenomics journal 20120401

• Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.

  Bone marrow transplantation 20120401

• In vitro antifungal activity of DNA topoisomerase inhibitors.

  Medical mycology 20120401

• Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

  Breast cancer research and treatment 20120401

• Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.

  Leukemia research 20120401

• Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.

  Molecular and cellular biochemistry 20120401

• Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.

  The Journal of pharmacology and experimental therapeutics 20120401

• Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.

  Anti-cancer drugs 20120401

• Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120401

• Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers.

  Cell death & disease 20120401

• The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.

  The oncologist 20120401

• [2012: Update on diagnosis and treatment of multiple sclerosis].

  Deutsche medizinische Wochenschrift (1946) 20120401

• Castration-resistant prostate cancer: systemic therapy in 2012.

  Clinics (Sao Paulo, Brazil) 20120401

• Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009.

  Croatian medical journal 20120401

• A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling.

  Marine drugs 20120401

• [Analysis of the characteristics of side population cells in the human ovarian cancer cell line OVCAR-3].

  Zhonghua fu chan ke za zhi 20120401

• Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

  Neurology 20120320

• Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Phospho-specific flow: fixating on the target.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.

  Leukemia & lymphoma 20120301

• Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.

  Leukemia & lymphoma 20120301

• High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).

  Leukemia & lymphoma 20120301

• Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.

  Molecular pharmacology 20120301

• [Second line therapy for castration-resistant prostate cancer (CRPC)].

  Der Urologe. Ausg. A 20120301

• Doxorubicin- and daunorubicin-induced regulation of Ca2+ and H+ fluxes through human bax inhibitor-1 reconstituted into membranes.

  Journal of pharmaceutical sciences 20120301

• Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.

  Pharmacological research 20120301

• Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells.

  Molecular medicine reports 20120301

• Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.

  American journal of hematology 20120301

• New induction and postinduction strategies in acute myeloid leukemia.

  Current opinion in hematology 20120301

• Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.

  BJU international 20120301

• Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

  Clinical genitourinary cancer 20120301

• ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.

  Chinese journal of cancer 20120301

• Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer.

  Photodiagnosis and photodynamic therapy 20120301

• Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120301

• Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

  Therapeutic advances in neurological disorders 20120301

• Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.

  Indian journal of endocrinology and metabolism 20120301

• Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations.

  Journal of nanoscience and nanotechnology 20120301

• Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

  Journal of the National Cancer Institute 20120222

• [Current treatment of acute myeloid leukaemia in adults].

  Orvosi hetilap 20120219

• Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

  ACS chemical biology 20120217

• Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells.

  Immunopharmacology and immunotoxicology 20120201

• A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride.

  Nanomedicine : nanotechnology, biology, and medicine 20120201

• Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.

  Cancer immunology, immunotherapy : CII 20120201

• B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells.

  Anti-cancer drugs 20120201

• Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.

  Drug metabolism and disposition: the biological fate of chemicals 20120201

• Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.

  Journal of drug targeting 20120201

• Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.

  Journal of clinical immunology 20120201

• Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.

  Journal of cancer research and clinical oncology 20120201

• [Hematological side effects of natalizumab: Correlation with clinical outcome].

  Revue neurologique 20120201

• StellaTUM: current consensus and discussion on pancreatic stellate cell research.

  Gut 20120201

• Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

  Cancer chemotherapy and pharmacology 20120201

• Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.

  Antiviral research 20120201

• Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201

• A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.

  Anticancer research 20120201

• Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.

  Journal of medicinal chemistry 20120126

• 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.

  FEBS letters 20120120

• Fluorescence properties of the Na⁺/H⁺exchanger inhibitor HMA (5-(N,N-hexamethylene)amiloride) are modulated by intracellular pH.

  European journal of histochemistry : EJH 20120120

• Prostate-specific membrane antigen-based therapeutics.

  Advances in urology 20120101

• Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.

  Journal of oncology 20120101

• Subcapsular orchiectomy in the primary therapy of patients with bone metastasis in advanced prostate cancer: an anachronistic intervention?

  Advances in urology 20120101

• The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8-10 disease.

  Advances in urology 20120101

• Mitoxantrone-loaded zeolite beta nanoparticles: preparation, physico-chemical characterization and biological evaluation.

  Journal of colloid and interface science 20120101

• Management of high-risk localized prostate cancer.

  Advances in urology 20120101

• Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells.

  Prostate cancer 20120101

• Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

  European journal of cancer (Oxford, England : 1990) 20120101

• Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120101

• Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.

  European neurology 20120101

• A rare case of supraspinatus tendon rupture.

  Annals of hematology 20120101

• Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

  Clinical & developmental immunology 20120101

• Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.

  World journal of surgical oncology 20120101

• Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development.

  Journal of oncology 20120101

• In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line.

  World journal of surgical oncology 20120101

• Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.

  Clinical Medicine Insights. Oncology 20120101

• Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.

  PloS one 20120101

• Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.

  Nucleosides, nucleotides & nucleic acids 20120101

• [Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].

  Der Urologe. Ausg. A 20120101

• Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

  Journal of neuroinflammation 20120101

• Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.

  Journal of hematology & oncology 20120101

• Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.

  Therapeutic advances in neurological disorders 20120101

• HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells.

  PloS one 20120101

• Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.

  Cell death & disease 20120101

• Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

  Drug design, development and therapy 20120101

• The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma.

  Advances in hematology 20120101

• Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial.

  Trials 20120101

• Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.

  Journal of experimental & clinical cancer research : CR 20120101

• Multiple sclerosis.

  BMJ clinical evidence 20120101

• Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy.

  International journal of nanomedicine 20120101

• Dilated cardiomyopathy following trastuzumab chemotherapy.

  Indian journal of pharmacology 20120101

• Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.

  Clinical Medicine Insights. Oncology 20120101

• Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment.

  TheScientificWorldJournal 20120101

• Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.

  PloS one 20120101

• Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3.

  Mediterranean journal of hematology and infectious diseases 20120101

• Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.

  BMC urology 20120101

• Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.

  PloS one 20120101

• Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

  PloS one 20120101

• Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

  Neurology research international 20120101

• Instability of (CTG)n•(CAG)n trinucleotide repeats and DNA synthesis.

  Cell & bioscience 20120101

• Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.

  PloS one 20120101

• Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

  PloS one 20120101

• Biochemical analysis of Cassia fistula aqueous extract and phytochemically synthesized gold nanoparticles as hypoglycemic treatment for diabetes mellitus.

  International journal of nanomedicine 20120101

• CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma.

  PloS one 20120101

• High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.

  PloS one 20120101

• Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines.

  PloS one 20120101

• Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration.

  Indian journal of ophthalmology 20120101

• Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.

  Advances in urology 20120101

• Redefining hormone sensitive disease in advanced prostate cancer.

  Advances in urology 20120101

• Interplaying factors that effect multiple sclerosis causation and sustenance.

  ISRN neurology 20120101

• Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance.

  PloS one 20120101

• State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.

  Clinical Medicine Insights. Oncology 20120101

• Plasma exchange in severe attacks of neuromyelitis optica.

  Multiple sclerosis international 20120101

• Immunotherapy of genitourinary malignancies.

  Journal of oncology 20120101

• Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.

  PloS one 20120101

• Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.

  PloS one 20120101

• Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

  PloS one 20120101

• Cryopreservation of ovarian tissue in pediatric patients.

  Obstetrics and gynecology international 20120101

• Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.

  PloS one 20120101

• Castration-resistant prostate cancer: mechanisms, targets, and treatment.

  Prostate cancer 20120101

• Natural killer cells: role in local tumor growth and metastasis.

  Biologics : targets & therapy 20120101

• Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

  Frontiers in microbiology 20120101

• Novel therapies for aggressive B-cell lymphoma.

  Advances in hematology 20120101

• Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.

  PloS one 20120101

• ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice.

  PloS one 20120101

• The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer.

  Advances in urology 20120101

• Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.

  Autoimmune diseases 20120101

• Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.

  Molecular medicine (Cambridge, Mass.) 20120101

• Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

  Clinical Medicine Insights. Oncology 20120101

• Implications of therapy-induced selective autophagy on tumor metabolism and survival.

  International journal of cell biology 20120101

• The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

  Indian journal of urology : IJU : journal of the Urological Society of India 20120101

• An overview of the evidence and mechanisms of herb-drug interactions.

  Frontiers in pharmacology 20120101

• JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.

  PloS one 20120101

• Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

  PloS one 20120101

• Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.

  Journal of cancer epidemiology 20120101

• Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.

  PloS one 20120101

• BOSS: context-enhanced search for biomedical objects.

  BMC medical informatics and decision making 20120101

• Therapeutic monitoring of immunotherapies in autoimmune diseases.

  Current pharmaceutical design 20120101

• Immune therapy of multiple sclerosis--future strategies.

  Current pharmaceutical design 20120101

• Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery.

  International journal of nanomedicine 20120101

• A study on solubilization of poorly soluble drugs by cyclodextrins and micelles: complexation and binding characteristics of sulfamethoxazole and trimethoprim.

  TheScientificWorldJournal 20120101

• Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer.

  ISRN urology 20120101

• Acute myeloid leukemia: focus on novel therapeutic strategies.

  Clinical Medicine Insights. Oncology 20120101

• Hepatocellular carcinoma: focus on different aspects of management.

  ISRN oncology 20120101

• Therapeutic strategies based on polymeric microparticles.

  Journal of biomedicine & biotechnology 20120101

• Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.

  Case reports in oncology 20120101

• Emerging targeted therapies for castration-resistant prostate cancer.

  Frontiers in endocrinology 20120101

• Is multiple sclerosis an autoimmune disease?

  Autoimmune diseases 20120101

• Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties.

  International journal of nanomedicine 20120101

• An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

  Case reports in medicine 20120101

• Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

  Advances in urology 20120101

• Structural analysis of Staphylococcus aureus serine/threonine kinase PknB.

  PloS one 20120101

• Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.

  ISRN oncology 20120101

• [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].

  Bulletin du cancer 20120101

• Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.

  PloS one 20120101

• Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.

  Congestive heart failure (Greenwich, Conn.) 20120101

• Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• Evidence for mitoxantrone-induced block of inwardly rectifying K(+) channels expressed in the osteoclast precursor RAW 264.7 cells differentiated with lipopolysaccharide.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.

  PloS one 20120101

• Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.

  Cancer cell international 20120101

• Sequencing of cabazitaxel in metastatic castrate-resistant prostate cancer: a case report.

  Case reports in oncology 20120101

• Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.

  PloS one 20120101

• Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20120101

• Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.

  Advances in hematology 20120101

• A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.

  PloS one 20120101

• Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.

  PloS one 20120101

• Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.

  PloS one 20120101

• Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

  Science (New York, N.Y.) 20111216

• Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20111215

• Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.

  Biochemical pharmacology 20111215

• ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.

  Oncogene 20111208

• FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.

  Medical oncology (Northwood, London, England) 20111201

• Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

  Journal of neurology, neurosurgery, and psychiatry 20111201

• Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results.

  Annals of hematology 20111201

• Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins.

  The Prostate 20111201

• Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.

  Cancer chemotherapy and pharmacology 20111201

• A population-based study of prostate cancer chemotherapy.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20111201

• Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

  Clinical lymphoma, myeloma & leukemia 20111201

• Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression.

  Cellular oncology (Dordrecht) 20111201

• Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models.

  Journal of animal science 20111201

• Current therapeutic options in pediatric multiple sclerosis.

  Current treatment options in neurology 20111201

• In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.

  Biochemical pharmacology 20111201

• Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.

  Haematologica 20111201

• Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA.

  Biomaterials 20111201

• Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

  Blood 20111201

• A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.

  Clinical immunology (Orlando, Fla.) 20111201

• Multiple sclerosis- diagnosis, management and prognosis.

  Australian family physician 20111201

• Side population cells in human gallbladder cancer cell line GBC-SD regulated by TGF-β-induced epithelial-mesenchymal transition.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Novel cytotoxic isolated from Jamaican Hyptis verticillata jacq induces apoptosis and overcomes multidrug resistance.

  Anticancer research 20111201

• [A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111201

• PEGylated liposomes modified with LHRH analogs for tumor targeting.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

  Neurology 20111122

• Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

  Blood 20111117

• Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.

  Cancer 20111115

• Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.

  Annals of hematology 20111101

• In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.

  Leukemia research 20111101

• Economic impact of disease progression in follicular non-Hodgkin lymphoma.

  Leukemia & lymphoma 20111101

• Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

  British journal of haematology 20111101

• Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

  Expert opinion on drug metabolism & toxicology 20111101

• Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930.

  Bioorganic & medicinal chemistry letters 20111101

• Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.

  Hematology reports 20111028

• Ongoing trials in low-grade lymphoma.

  Hematology reports 20111028

• Case studies of elderly patients with non-Hodgkin's lymphoma.

  Hematology reports 20111028

• A comprehensive outlook on intracerebral therapy of malignant gliomas.

  Critical reviews in oncology/hematology 20111001

• [Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].

  Der Nervenarzt 20111001

• Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling.

  Aging 20111001

• Chemotherapy-based treatment for castration-resistant prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110920

• Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

  Biochemistry 20110920

• Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

  Annals of hematology 20110901

• The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

  Cancer 20110901

• Tissue concentration of systemically administered antineoplastic agents in human brain tumors.

  Journal of neuro-oncology 20110901

• Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.

  Clinical neurology and neurosurgery 20110901

• Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study.

  Neurosurgery 20110901

• Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma.

  Anti-cancer drugs 20110901

• MS Forum/MS Over the Past 17 Years.

  International MS journal 20110901

• ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20110901

• A case of pseudomembranous colitis after voriconazole therapy.

  Yonsei medical journal 20110901

• Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• Second-line therapy for castrate-resistant prostate cancer: a literature review.

  Asia-Pacific journal of clinical oncology 20110901

• [A case of neuromyelitis optica with varicella zoster virus meningitis during mitoxantrone treatment].

  Rinsho shinkeigaku = Clinical neurology 20110901

• Second primary glioblastoma multiforme following autologous hematopoietic stem cell transplantation in a patient with acute myelogenous leukemia.

  Cancer research and treatment : official journal of Korean Cancer Association 20110901

• Low-grade lymphoma: Beyond fludarabine-single therapy.

  The Korean journal of hematology 20110901

• Fortuitous detection of esophageal pneumatosis in a neutropenic patient.

  The Korean journal of hematology 20110901

• Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.

  The Korean journal of hematology 20110901

• [Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].

  Hinyokika kiyo. Acta urologica Japonica 20110901

• New insights into neuromyelitis optica.

  Journal of clinical neurology (Seoul, Korea) 20110901

• [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110901

• Multiple sclerosis: pathogenesis and treatment.

  Current neuropharmacology 20110901

• Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

  Current neuropharmacology 20110901

• Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

  Current neuropharmacology 20110901

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.

  Journal of medicinal chemistry 20110825

• A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.

  Journal of the neurological sciences 20110815

• A special case of acute leukemia in childhood.

  Journal of medicine and life 20110815

• The changing therapeutic landscape of castration-resistant prostate cancer.

  Nature reviews. Clinical oncology 20110809

• High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow.

  Cellular oncology (Dordrecht) 20110801

• Pathways of chemotherapy resistance in castration-resistant prostate cancer.

  Endocrine-related cancer 20110801

• Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.

  Acta biochimica et biophysica Sinica 20110801

• Use of mitoxantrone in neuromyelitis optica.

  Archives of neurology 20110801

• New treatment options for castrate-resistant prostate cancer: a urology perspective.

  The Canadian journal of urology 20110801

• Development of acute megakaryoblastic leukemia with isochromosome (12p) after a primary mediastinal germ cell tumor in Korea.

  Journal of Korean medical science 20110801

• Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital.

  Clinics (Sao Paulo, Brazil) 20110801

• Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.

  Chonnam medical journal 20110801

• What's up with down syndrome and leukemia-A lot!

  Pediatric blood & cancer 20110715

• Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.

  Pediatric blood & cancer 20110715

• Mitoxantrone induced impediment of histone acetylation and structural flexibility of the protein.

  Cell biochemistry and biophysics 20110701

• Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

  Leukemia research 20110701

• Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20110701

• High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

  Cancer immunology, immunotherapy : CII 20110701

• MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

  Biochemical pharmacology 20110701

• Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents.

  Tuberculosis (Edinburgh, Scotland) 20110701

• Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

  Molecular cancer therapeutics 20110701

• Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse.

  Reproductive sciences (Thousand Oaks, Calif.) 20110701

• Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.

  Pharmacogenomics 20110701

• Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.

  Cell death & disease 20110701

• Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.

  PLoS computational biology 20110701

• Treatment of multiple sclerosis.

  Annals of Indian Academy of Neurology 20110701

• Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.

  Korean journal of urology 20110701

• Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines.

  Korean journal of urology 20110701

• [Preparation of a hyaluronic acid modified bovine serum albumin nanoparticle and its anti-tumor effect].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110701

• Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble.

  Nature chemical biology 20110626

• A pH-responsive cleavage route based on a metal-organic coordination bond.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110620

• Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.

  Journal of neuro-oncology 20110601

• Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.

  Annals of hematology 20110601

• Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2-overexpressing resistant breast cancer cells compared with their drug-sensitive parental line.

  DNA and cell biology 20110601

• A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

  Leukemia 20110601

• Multiple sclerosis: current treatment algorithms.

  Current opinion in neurology 20110601

• Broadening horizons in medical management of prostate cancer.

  Acta oncologica (Stockholm, Sweden) 20110601

• Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?

  Haematologica 20110601

• Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.

  Expert review of neurotherapeutics 20110601

• Targeting mTOR for the treatment of AML. New agents and new directions.

  Oncotarget 20110601

• Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.

  Clinical advances in hematology & oncology : H&O 20110601

• Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Asymmetric enzymatic glycosylation of mitoxantrone.

  Organic letters 20110520

• Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.

  Neurology 20110517

• Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.

  Bioorganic & medicinal chemistry letters 20110515

• Cytotoxic and PPARs transcriptional activities of sterols from the Vietnamese soft coral Lobophytum laevigatum.

  Bioorganic & medicinal chemistry letters 20110515

• Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.

  Journal of medicinal chemistry 20110512

• Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20110501

• 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.

  Pharmaceutical research 20110501

• Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi.

  International journal of antimicrobial agents 20110501

• [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].

  Actas dermo-sifiliograficas 20110501

• Managing MS in a changing treatment landscape.

  Journal of neurology 20110501

• Definitions of breakthrough disease and second-line agents.

  Neurologic clinics 20110501

• Promising emerging therapies for multiple sclerosis.

  Neurologic clinics 20110501

• CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.

  Epigenetics 20110501

• Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.

  The American journal of managed care 20110501

• Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.

  The American journal of managed care 20110501

• Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.

  Journal of oncology practice 20110501

• Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

  Cancer research 20110415

• Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone.

  Acta neurologica Scandinavica 20110401

• T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression.

  Annals of hematology 20110401

• Drug-induced Sweet's syndrome after mitoxantrone therapy in a patient with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20110401

• Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.

  Archives of neurology 20110401

• Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.

  Haematologica 20110401

• Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.

  Pediatric hematology and oncology 20110401

• Cytotoxic and antioxidant activities of diterpenes and sterols from the Vietnamese soft coral Lobophytum compactum.

  Bioorganic & medicinal chemistry letters 20110401

• Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.

  BJU international 20110401

• Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  European urology 20110401

• Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial.

  European urology 20110401

• TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.

  Future oncology (London, England) 20110401

• The effect of mitoxantrone as an anticancer drug on hepatocytes nuclei and chromatin: Selective release of histone proteins.

  Indian journal of pharmacology 20110401

• Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

  Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401

• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

  Blood 20110324

• Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.

  Neurology 20110322

• Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.

  Biochemical pharmacology 20110315

• Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

  Journal of cancer research and clinical oncology 20110301

• Race and intensity of post-remission therapy in acute myeloid leukemia.

  Leukemia research 20110301

• Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• Application of magnetic nanoparticles in pharmaceutical sciences.

  Pharmaceutical research 20110301

• In vivo methods to study uptake of nanoparticles into the brain.

  Pharmaceutical research 20110301

• Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

  Cancer 20110301

• Salvaging AML with CLAG: novel option, or more of the same?

  Leukemia research 20110301

• Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

  Leukemia research 20110301

• A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.

  Japanese journal of clinical oncology 20110301

• Investigating the enhancement of cisplatin cytotoxicity on 5637 cells by combination with mogoltacin.

  Toxicology in vitro : an international journal published in association with BIBRA 20110301

• Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Cabazitaxel: a new drug for metastatic prostate cancer.

  Asian journal of andrology 20110301

• A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

  British journal of haematology 20110301

• Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

  Cancer investigation 20110301

• Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.

  Plant signaling & behavior 20110301

• Castration-resistant prostate cancer: targeted therapies and individualized treatment.

  The oncologist 20110301

• Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.

  Anti-cancer agents in medicinal chemistry 20110301

• Current treatment strategies for castration-resistant prostate cancer.

  Korean journal of urology 20110301

• Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.

  The Korean journal of hematology 20110301

• Mitoxantrone improves the survival of children with first relapse of ALL.

  Nature reviews. Clinical oncology 20110301

• Depressogenic effects of medications: a review.

  Dialogues in clinical neuroscience 20110301

• Saudi Oncology Society clinical management guidelines for prostate cancer.

  Urology annals 20110301

• Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia.

  Korean journal of pediatrics 20110301

• Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data.

  Journal of breast cancer 20110301

• Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.

  British journal of cancer 20110215

• A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.

  British journal of cancer 20110215

• Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.

  British journal of cancer 20110215

• Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.

  Cancer chemotherapy and pharmacology 20110201

• Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.

  Journal of cancer research and clinical oncology 20110201

• A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.

  Cancer chemotherapy and pharmacology 20110201

• The relevance of animal models in multiple sclerosis research.

  Pathophysiology : the official journal of the International Society for Pathophysiology 20110201

• Spectral studies on the molecular interaction of anticancer drug mitoxantrone with CTAB micelles.

  Journal of pharmaceutical sciences 20110201

• Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase.

  Biochimie 20110201

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats.

  Pharmacogenetics and genomics 20110201

• Spirituality and end-of-life care in disadvantaged men dying of prostate cancer.

  World journal of urology 20110201

• Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.

  Current atherosclerosis reports 20110201

• Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110201

• The role of RANK-ligand inhibition in cancer: the story of denosumab.

  The oncologist 20110201

• Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.

  Neuropediatrics 20110201

• Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.

  Blood 20110120

• Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

  Blood 20110113

• Cabazitaxel for castration-resistant prostate cancer.

  Lancet (London, England) 20110108

• Cabazitaxel for castration-resistant prostate cancer.

  Lancet (London, England) 20110108

• Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.

  The Prostate 20110101

• Effects of methimazole on the elimination of irinotecan.

  Cancer chemotherapy and pharmacology 20110101

• Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane.

  Biochimica et biophysica acta 20110101

• [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].

  Revue neurologique 20110101

• Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

  Cancer immunology, immunotherapy : CII 20110101

• Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.

  Naunyn-Schmiedeberg's archives of pharmacology 20110101

• Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

  Virchows Archiv : an international journal of pathology 20110101

• Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution.

  International journal of biological macromolecules 20110101

• Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20110101

• Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).

  Current medicinal chemistry 20110101

• Cabazitaxel for the treatment of castration-resistant prostate cancer.

  Future oncology (London, England) 20110101

• Testing for HER2 in Breast Cancer: A Continuing Evolution.

  Pathology research international 20110101

• Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.

  European neurology 20110101

• Prognostic factors for failure after prostatectomy.

  Journal of Cancer 20110101

• Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.

  Autoimmune diseases 20110101

• Recurrent neurotropic chloroma: report of a case and review of the literature.

  Advances in hematology 20110101

• Biochemical and pharmacological effects of mitoxantrone and acetyl-L-carnitine in mice with a solid form of Ehrlich tumour.

  Chemotherapy 20110101

• Intra-arterial mitoxantrone/paclitaxel in angiosarcoma of the lower limb associated with chronic lymphedema (Stewart-Treves syndrome) in a patient with cervical cancer.

  European journal of dermatology : EJD 20110101

• Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes.

  Autoimmune diseases 20110101

• Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).

  Journal of medical Internet research 20110101

• Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

  BMC cancer 20110101

• Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance.

  PloS one 20110101

• FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.

  Journal of experimental & clinical cancer research : CR 20110101

• Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

  PloS one 20110101

• Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

  Therapeutics and clinical risk management 20110101

• A novel pathway of TEF regulation mediated by microRNA-125b contributes to the control of actin distribution and cell shape in fibroblasts.

  PloS one 20110101

• Management of optic neuritis.

  Indian journal of ophthalmology 20110101

• Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

  BMC neurology 20110101

• Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.

  BMC cancer 20110101

• Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.

  Diagnostic pathology 20110101

• Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.

  Patient preference and adherence 20110101

• Current disease-modifying treatment of multiple sclerosis.

  The Mount Sinai journal of medicine, New York 20110101

• Molecular modeling study of interaction of anthracenedione class of drug mitoxantrone and its analogs with DNA tetrameric sequences.

  Advances in experimental medicine and biology 20110101

• Therapeutics formulated to target cancer stem cells: Is it in our future?

  Cancer cell international 20110101

• Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.

  Pharmacological reports : PR 20110101

• [Energetics of complex formation of the DNA hairpin structure d(GCGAAGC) with aromatic ligands].

  Biofizika 20110101

• Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study.

  Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110101

• Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

  Drug design, development and therapy 20110101

• Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.

  Patient preference and adherence 20110101

• Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.

  BMC cancer 20110101

• Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

  Journal of hematology & oncology 20110101

• An illustrative case of subcutaneous panniculitis-like T-cell lymphoma.

  Journal of skin cancer 20110101

• Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.

  Core evidence 20110101

• Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.

  Molecular cancer 20110101

• An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development.

  Journal of Cancer 20110101

• A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.

  Journal of experimental & clinical cancer research : CR 20110101

• Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.

  BMC medicine 20110101

• Vulnerability to oxidative stress in vitro in pathophysiology of mitochondrial short-chain acyl-CoA dehydrogenase deficiency: response to antioxidants.

  PloS one 20110101

• [Severe skin reaction with mucous membrane inflammation during MINE chemotherapy].

  Annales de dermatologie et de venereologie 20110101

• Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

  Sarcoma 20110101

• Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

  Journal of hematology & oncology 20110101

• Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

  Breast cancer research : BCR 20110101

• SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes.

  PloS one 20110101

• Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

  PloS one 20110101

• Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

  Autoimmune diseases 20110101

• Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

  Journal of translational medicine 20110101

• Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.

  Trials 20110101

• Optimized purification of a heterodimeric ABC transporter in a highly stable form amenable to 2-D crystallization.

  PloS one 20110101

• High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.

  PloS one 20110101

• Development of oral immunomodulatory agents in the management of multiple sclerosis.

  Drug design, development and therapy 20110101

• The effect of ATM and ERK1/2 inhibition on mitoxantrone-induced cell death of leukaemic cells.

  Folia biologica 20110101

• Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy.

  BMC biology 20110101

• Review of cardiotoxicity in pediatric cancer patients: during and after therapy.

  Cardiology research and practice 20110101

• High throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screening.

  PloS one 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

  BMC cancer 20110101

• P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.

  BMC cancer 20110101

• Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.

  Journal of biomedical science 20110101

• An update on TroVax for the treatment of progressive castration-resistant prostate cancer.

  OncoTargets and therapy 20110101

• Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole.

  Molecular systems biology 20110101

• Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

  Clinical Medicine Insights. Oncology 20110101

• Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma.

  Clinical Medicine Insights. Oncology 20110101

• Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies.

  Nanoscale research letters 20110101

• Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets.

  International journal of nanomedicine 20110101

• Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation.

  Current medicinal chemistry 20110101

• Abiraterone acetate, an inhibitor of adrenal androgen synthesis in 'hormone refractory prostate cancer'.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20110101

• Atypical Burkitt's lymphoma transforming from follicular lymphoma.

  Diagnostic pathology 20110101

• A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin.

  Case reports in oncology 20110101

• Language impairment and right hemiparesis in a 54-year-old woman.

  Frontiers in neurology 20110101

• Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.

  Journal of oncology 20110101

• Novel molecular markers of malignancy in histologically normal and benign breast.

  Pathology research international 20110101

• Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

  PloS one 20110101

• Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.

  OncoTargets and therapy 20110101

• Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.

  Cancer management and research 20110101

• Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

  Cancer management and research 20110101

• Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters.

  PloS one 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

  Neuropsychiatric disease and treatment 20110101

• ATP-binding cassette transporters in inflammatory brain disease.

  Current pharmaceutical design 20110101

• Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma.

  Journal of nanobiotechnology 20110101

• The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.

  Molecular cancer 20110101

• Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.

  Chinese medicine 20110101

• Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.

  BMC cell biology 20110101

• Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.

  BMC cancer 20110101

• Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.

  Mediterranean journal of hematology and infectious diseases 20110101

• Protein-binding microarray analysis of tumor suppressor AP2α target gene specificity.

  PloS one 20110101

• Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT.

  PloS one 20110101

• BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.

  PloS one 20110101

• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

  ASN neuro 20110101

• Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

  Clinical proteomics 20110101

• High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model.

  PloS one 20110101

• An overview of the rare parotid gland cancer.

  Head & neck oncology 20110101

• Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy.

  International journal of nanomedicine 20110101

• Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.

  Neuropsychiatric disease and treatment 20110101

• ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.

  Diagnostic pathology 20110101

• Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

  BMC cancer 20110101

• Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.

  OncoTargets and therapy 20110101

• [Contribution of enthalpy to the energetics of complex formation of aromatic ligands with DNA].

  Biofizika 20110101

• Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms.

  Journal of hematology & oncology 20110101

• Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.

  Neurology research international 20110101

• Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis.

  Journal of pharmacy & bioallied sciences 20110101

• Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles.

  PloS one 20110101

• Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

  BMC neurology 20110101

• Inhibition of unwinding and ATPase activities of Plasmodium falciparum Dbp5/DDX19 homolog.

  Communicative & integrative biology 20110101

• Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

  Molecular cancer 20110101

• Dimerization of ABCG2 analysed by bimolecular fluorescence complementation.

  PloS one 20110101

• Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines.

  BMC cancer 20110101

• Targeted therapy in hepatocellular carcinoma.

  International journal of hepatology 20110101

• The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer.

  International archives of medicine 20110101

• Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.

  Frontiers in pharmacology 20110101

• Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management.

  Obstetrics and gynecology international 20110101

• Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.

  Journal of translational medicine 20110101

• Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast.

  BMC biology 20110101

• Musashi1 expression cells derived from mouse embryonic stem cells can be enriched in side population isolated by fluorescence activated cell sorter.

  BMC cell biology 20110101

• Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.

  BMC cancer 20110101

• Antioxidant Activities of Plumbagin and Its Cu (II) Complex.

  Bioinorganic chemistry and applications 20110101

• Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

  PloS one 20110101

• Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy.

  Bone marrow research 20110101

• Oncolytic virotherapy for multiple myeloma: past, present, and future.

  Bone marrow research 20110101

• Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis.

  Bone marrow research 20110101

• HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.

  BMC genomics 20110101

• Gout, genetics and ABC transporters.

  F1000 biology reports 20110101

• Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells.

  PloS one 20110101

• The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.

  BMC neurology 20110101

• A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.

  Journal of hematology & oncology 20110101

• Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

  Clinical Medicine Insights. Oncology 20110101

• Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

  Multiple sclerosis international 20110101

• Potential impact of B cells on T cell function in multiple sclerosis.

  Multiple sclerosis international 20110101

• When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

  Multiple sclerosis international 20110101

• Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.

  Prostate cancer 20110101

• Disordering of human telomeric G-quadruplex with novel antiproliferative anthrathiophenedione.

  PloS one 20110101

• Myeloid sarcoma in a one-month-old infant.

  Case reports in dermatology 20110101

• What role for angiogenesis in childhood acute lymphoblastic leukaemia?

  Advances in hematology 20110101

• Neuromyelitis optica spectrum disease with positive autoimmune indices: a case report and review of the literature.

  Case reports in medicine 20110101

• Molecular pathogenesis of secondary acute promyelocytic leukemia.

  Mediterranean journal of hematology and infectious diseases 20110101

• Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.

  International journal of nanomedicine 20110101

• Mitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms.

  Folia biologica 20110101

• Myasthenia Gravis during the Course of Neuromyelitis Optica.

  Case reports in neurology 20110101

• Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis.

  Journal of signal transduction 20110101

• Attenuation of cytotoxic natural product DNA intercalating agents by caffeine.

  Scientia pharmaceutica 20110101

• Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.

  Drug metabolism and drug interactions 20110101

• In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line.

  Cancer cell international 20110101

• Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial.

  BMC cancer 20110101

• Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia.

  Stem cells international 20110101

• Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

  PloS one 20110101

• Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors.

  Journal of translational medicine 20110101

• Binding of tetracycline and chlortetracycline to the enzyme trypsin: spectroscopic and molecular modeling investigations.

  PloS one 20110101

• Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.

  PloS one 20110101

• Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era.

  Mediterranean journal of hematology and infectious diseases 20110101

• Clinical features and treatment outcome of acute promyelocytic leukemia patients treated at cairo national cancer institute in egypt.

  Mediterranean journal of hematology and infectious diseases 20110101

• Newly diagnosed acute promyelocytic leukemia.

  Mediterranean journal of hematology and infectious diseases 20110101

• Incidence of acute myeloid leukemia after breast cancer.

  Mediterranean journal of hematology and infectious diseases 20110101

• Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab.

  Neurology research international 20110101

• Lipodystrophy in HIV patients: its challenges and management approaches.

  HIV/AIDS (Auckland, N.Z.) 20110101

• The prospective role of plant products in radiotherapy of cancer: a current overview.

  Frontiers in pharmacology 20110101

• Multidrug resistance in breast cancer: from in vitro models to clinical studies.

  International journal of breast cancer 20110101

• [Treatment of elderly patients with non-Hodgkin's lymphoma].

  Likars'ka sprava 20110101

• A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Cell death signaling and anticancer therapy.

  Frontiers in oncology 20110101

• Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.

  Cancer biology & therapy 20101215

• Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

  Lancet (London, England) 20101211

• Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

  Lancet (London, England) 20101211

• Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial.

  Lancet (London, England) 20101211

• Cancer and renal insufficiency results of the BIRMA study.

  British journal of cancer 20101207

• Flower-like hierarchically nanostructured hydroxyapatite hollow spheres: facile preparation and application in anticancer drug cellular delivery.

  Chemistry, an Asian journal 20101203

• Effect of mitoxantrone on proliferation dynamics and cell-cycle progression.

  Bioscience reports 20101201

• Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes.

  Nanomedicine : nanotechnology, biology, and medicine 20101201

• Translation of novel anti-cancer cytotoxicity biomarkers detected with high content analysis from an in vitro predictive model to an in vivo cell model.

  Toxicology in vitro : an international journal published in association with BIBRA 20101201

• Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.

  Clinical neurology and neurosurgery 20101201

• Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20101201

• Receptor for activated C-kinase 1 regulates the cell surface expression and function of ATP binding cassette G2.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

  Molecular cancer therapeutics 20101201

• Identification of specific inhibitors for a trypanosomatid RNA editing reaction.

  RNA (New York, N.Y.) 20101201

• Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activities.

  Bioorganic & medicinal chemistry letters 20101201

• Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

  Leukemia 20101201

• [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

  Der Nervenarzt 20101201

• Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.

  Acta biochimica et biophysica Sinica 20101201

• [Actualities in prostate cancer in ASCO annual meeting 2010].

  Bulletin du cancer 20101201

• A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.

  PLoS neglected tropical diseases 20101201

• The DAC system and associations with acute leukemias and myelodysplastic syndromes.

  Investigational new drugs 20101201

• A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

  Clinical lymphoma, myeloma & leukemia 20101201

• The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell.

  Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20101201

• Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era.

  Cancer research and treatment : official journal of Korean Cancer Association 20101201

• Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol.

  The Korean journal of hematology 20101201

• A renaissance in the medical treatment of advanced prostate cancer.

  Oncology (Williston Park, N.Y.) 20101201

• [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].

  Yao xue xue bao = Acta pharmaceutica Sinica 20101201

• Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.

  Bioorganic & medicinal chemistry 20101115

• Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.

  British journal of cancer 20101109

• The anti-oxidative role of ABCG2 in corneal epithelial cells.

  Investigative ophthalmology & visual science 20101101

• Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.

  American journal of physiology. Cell physiology 20101101

• Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.

  European journal of medicinal chemistry 20101101

• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.

  American journal of hematology 20101101

• Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.

  Molecular cancer research : MCR 20101101

• New biomarkers probing depth of cell senescence assessed by laser scanning cytometry.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20101101

• TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population.

  British journal of cancer 20101101

• [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].

  Zhonghua fu chan ke za zhi 20101101

• Refractory chronic lymphocytic leukemia--new therapeutic strategies.

  Oncotarget 20101101

• ABCG2 transports and transfers heme to albumin through its large extracellular loop.

  The Journal of biological chemistry 20101022

• Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

  Cancer research 20101015

• On-line chemiluminescence determination of mitoxantrone by capillary electrophoresis.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015

• New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

  Journal of medicinal chemistry 20101014

• Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

  European journal of pharmacology 20101010

• Cabazitaxel in prostate cancer: stretching a string.

  Lancet (London, England) 20101002

• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  Lancet (London, England) 20101002

• Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines.

  Acta neurologica Scandinavica 20101001

• Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.

  Breast cancer research and treatment 20101001

• Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

  Cancer chemotherapy and pharmacology 20101001

• Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.

  Human gene therapy 20101001

• Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.

  Brain : a journal of neurology 20101001

• Current and future role of interferon beta in the therapy of multiple sclerosis.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20101001

• Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia.

  Clinical lymphoma, myeloma & leukemia 20101001

• Acute promyelocytic leukemia in HIV-infected adults: a case report and review of therapeutic considerations.

  Clinical lymphoma, myeloma & leukemia 20101001

• Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

  World journal of cardiology 20100926

• Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).

  Cancer 20100915

• Pharmacoeconomic considerations in the treatment of multiple sclerosis.

  Drugs 20100910

• Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

  British journal of cancer 20100907

• Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

  Medical oncology (Northwood, London, England) 20100901

• A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.

  Medical oncology (Northwood, London, England) 20100901

• Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.

  Medical oncology (Northwood, London, England) 20100901

• Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.

  Cancer chemotherapy and pharmacology 20100901

• Off-line memory consolidation impairments in multiple sclerosis patients receiving high-dose corticosteroid treatment mirror consolidation impairments in depression.

  Psychoneuroendocrinology 20100901

• Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

  Haematologica 20100901

• Emerging therapies in relapsing-remitting multiple sclerosis.

  Reviews on recent clinical trials 20100901

• Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

  Journal of materials science. Materials in medicine 20100901

• Advances in multiple sclerosis research in 2009.

  Journal of neurology 20100901

• Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

  Current drug metabolism 20100901

• [Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody].

  Brain and nerve = Shinkei kenkyu no shinpo 20100901

• Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse.

  The Korean journal of hematology 20100901

• Chemotherapeutics in the treatment of multiple sclerosis.

  Therapeutic advances in neurological disorders 20100901

• Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.

  Current neuropharmacology 20100901

• Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells.

  Cell death & disease 20100901

• Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100815

• Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells.

  FEBS letters 20100804

• Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity.

  Nanomedicine : nanotechnology, biology, and medicine 20100801

• Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100801

• Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.

  BJU international 20100801

• BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.

  Cancer science 20100801

• Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.

  Genes, chromosomes & cancer 20100801

• Quality indicators for multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20100801

• Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.

  Expert opinion on pharmacotherapy 20100801

• [Current treatment of multiple sclerosis].

  La Revue de medecine interne 20100801

• Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20100801

• Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

  Assay and drug development technologies 20100801

• Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.

  Molecular cancer therapeutics 20100801

• Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.

  Arquivos de neuro-psiquiatria 20100801

• Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles.

  Archives of pharmacal research 20100801

• Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

  Drugs 20100730

• The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

  British journal of cancer 20100727

• Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone.

  ChemMedChem 20100705

• Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells.

  Cancer chemotherapy and pharmacology 20100701

• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Leukemia research 20100701

• Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

  Pharmaceutical research 20100701

• Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?

  Leukemia research 20100701

• Evidence for a two-stage disability progression in multiple sclerosis.

  Brain : a journal of neurology 20100701

• Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

  Cancer investigation 20100701

• Optical extinction combined with phase measurements for probing DNA-small-molecule interactions using an evanescent waveguide biosensor.

  Analytical chemistry 20100701

• Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.

  Biopharmaceutics & drug disposition 20100701

• Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

  Blood 20100624

• Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.

  Bioorganic & medicinal chemistry 20100615

• Elevated XIAP expression alone does not confer chemoresistance.

  British journal of cancer 20100608

• Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

  Investigational new drugs 20100601

• Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.

  Bone marrow transplantation 20100601

• Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100601

• Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.

  Molecular and cellular biochemistry 20100601

• Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines.

  Anti-cancer drugs 20100601

• An instrument-based screening assay for DNA-targeted anticancer drugs using resonance light scattering.

  Combinatorial chemistry & high throughput screening 20100601

• Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.

  The Journal of pharmacology and experimental therapeutics 20100601

• Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

  The Journal of pharmacology and experimental therapeutics 20100601

• Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

  Neurology 20100601

• Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

  PLoS pathogens 20100601

• Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.

  Leukemia & lymphoma 20100601

• A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.

  Hematology (Amsterdam, Netherlands) 20100601

• [Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20100601

• Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.

  Anticancer research 20100601

• Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

  Current neuropharmacology 20100601

• Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission.

  The Korean journal of hematology 20100601

• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  Chemistry & biology 20100528

• Coupled spectral and electrochemical evaluation of the anticancer drug mitoxantrone-sodium dodecyl sulfate interaction.

  International journal of pharmaceutics 20100510

• Immunotherapy and multiple sclerosis: The devil is in the details.

  Neurology 20100504

• Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Neurology 20100504

• Pharmacokinetics and biliary excretion of mitoxantrone in rats.

  Journal of pharmaceutical sciences 20100501

• Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin.

  Nucleic acids research 20100501

• Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

  Pediatric blood & cancer 20100501

• Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.

  Pharmacoepidemiology and drug safety 20100501

• DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.

  International journal of oncology 20100501

• Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.

  Journal of Korean medical science 20100501

• [Diagnosis and therapy in multiple sclerosis].

  Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20100501

• Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study.

  Anticancer research 20100501

• A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis.

  Archives of medical science : AMS 20100430

• Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.

  British journal of cancer 20100427

• Inhibition of transcription factor assembly and structural stability on mitoxantrone binding with DNA.

  Bioscience reports 20100421

• Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.

  The Journal of biological chemistry 20100416

• Screening DNA-targeted anticancer drug in vitro based on the drug-conjugated DNA by resonance light scattering technique.

  Biosensors & bioelectronics 20100415

• Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.

  British journal of cancer 20100413

• Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis.

  Journal of neurology, neurosurgery, and psychiatry 20100401

• Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.

  American journal of physiology. Renal physiology 20100401

• Synthesis, cytotoxicity and DNA-binding of novel bisnaphthalimidopropyl derivatives in breast cancer MDA-MB-231 cells.

  European journal of medicinal chemistry 20100401

• Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006.

  The Journal of antimicrobial chemotherapy 20100401

• KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.

  Biological chemistry 20100401

• Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

  Archives of neurology 20100401

• Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

  Cancer 20100401

• (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20100401

• Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.

  Thyroid : official journal of the American Thyroid Association 20100401

• Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

  American journal of clinical pathology 20100401

• Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.

  Drug and chemical toxicology 20100401

• Current and future disease-modifying therapies in multiple sclerosis.

  International journal of clinical practice 20100401

• Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments.

  Journal of pharmacy practice 20100401

• Multiple sclerosis: closing in on an oral treatment.

  Nature 20100318

• Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

  Biochemistry 20100316

• Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

  Neurology 20100316

• The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

  Structure (London, England : 1993) 20100314

• [Pharmacological treatment of multiple sclerosis].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20100311

• Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

  Leukemia research 20100301

• Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma.

  Annals of hematology 20100301

• Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes.

  Toxicology in vitro : an international journal published in association with BIBRA 20100301

• CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

  The Prostate 20100301

• Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.

  American journal of hematology 20100301

• Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• miR-181a and miR-630 regulate cisplatin-induced cancer cell death.

  Cancer research 20100301

• Triterpene compounds isolated from Acer mandshuricum and their anti-inflammatory activity.

  Bioorganic & medicinal chemistry letters 20100301

• Combination therapy in multiple sclerosis.

  The Lancet. Neurology 20100301

• Heart transplant in a childhood leukemia survivor: a case report.

  Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20100301

• Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.

  Veterinary and comparative oncology 20100301

• Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

  British journal of clinical pharmacology 20100301

• Past, present and future therapeutics for cerebellar ataxias.

  Current neuropharmacology 20100301

• A case of donor-derived granulocytic sarcoma after allogeneic hematopoietic stem cell transplantation.

  The Korean journal of hematology 20100301

• HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study.

  Journal of pharmaceutical and biomedical analysis 20100205

• Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs.

  Nanomedicine : nanotechnology, biology, and medicine 20100201

• The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

  European journal of cancer (Oxford, England : 1990) 20100201

• Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100201

• Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.

  Chinese journal of cancer 20100201

• [Effect of physical exercise on the efficacy of mitoxantrone-loaded nanoparticles in treating early breast cancer].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20100201

• Dural MALT lymphoma with disseminated disease.

  Hematology reports 20100126

• Clinical case of acute myeloblastic leukemia with t(8;21)(q22;q22) in a patient with Klinefelter's syndrome.

  Hematology reports 20100126

• PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.

  British journal of cancer 20100119

• MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells.

  International journal of pharmaceutics 20100115

• Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

  Blood 20100114

• Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

  Journal of the National Cancer Institute 20100106

• Mitoxantrone and cytotoxic drugs' mechanisms of action.

  Neurology 20100105

• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

  Cancer chemotherapy and pharmacology 20100101

• The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.

  Phytotherapy research : PTR 20100101

• Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

  Cellular and molecular neurobiology 20100101

• Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

  Drug metabolism and disposition: the biological fate of chemicals 20100101

• VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.

  Archives of gerontology and geriatrics 20100101

• Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells.

  Bioorganic & medicinal chemistry letters 20100101

• In vitro transcription assay for resolution of drug-DNA interactions at defined DNA sequences.

  Methods in molecular biology (Clifton, N.J.) 20100101

• Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.

  BMC cancer 20100101

• An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.

  Cases journal 20100101

• Molecular interaction studies of trimethoxy flavone with human serum albumin.

  PloS one 20100101

• MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

  BMC cancer 20100101

• Neuro-muscular differentiation of adult porcine skin derived stem cell-like cells.

  PloS one 20100101

• Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.

  PloS one 20100101

• [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100101

• Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

  Patient preference and adherence 20100101

• Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

  Obstetrics and gynecology international 20100101

• Angiogenesis inhibition in prostate cancer: current uses and future promises.

  Journal of oncology 20100101

• A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

  Journal of translational medicine 20100101

• [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].

  Vnitrni lekarstvi 20100101

• Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

  BMC cancer 20100101

• Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.

  Journal of experimental & clinical cancer research : CR 20100101

• Temozolomide-induced myelodysplasia.

  Advances in hematology 20100101

• The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

  International journal of cell biology 20100101

• [Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].

  Terapevticheskii arkhiv 20100101

• Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.

  PloS one 20100101

• Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer.

  Case reports in medicine 20100101

• Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.

  Journal of cardiothoracic surgery 20100101

• A theoretical quantitative model for evolution of cancer chemotherapy resistance.

  Biology direct 20100101

• Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.

  Journal of hematology & oncology 20100101

• Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

  PloS one 20100101

• Non-Hodgkin's lymphoma presenting as a primary bladder tumor: a case report.

  Journal of medical case reports 20100101

• Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis.

  Therapeutics and clinical risk management 20100101

• Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

  Therapeutics and clinical risk management 20100101

• Cancer stem cells in solid tumors: elusive or illusive?

  Cell communication and signaling : CCS 20100101

• Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation.

  Journal of neuroinflammation 20100101

• Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV.

  Journal of biomedicine & biotechnology 20100101

• Treatment outcome of acute promyelocytic leukemia with modified aida protocol.

  Advances in hematology 20100101

• TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

  BMC cancer 20100101

• Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

  BMC cancer 20100101

• Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

  Journal of oncology 20100101

• Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR.

  BMC infectious diseases 20100101

• Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.

  BMC cancer 20100101

• Modified intention to treat reporting in randomised controlled trials: systematic review.

  BMJ (Clinical research ed.) 20100101

• Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.

  BMC cancer 20100101

• Clinical trials with anti-angiogenic agents in hematological malignancies.

  Journal of angiogenesis research 20100101

• Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.

  BMC cancer 20100101

• Update on options for treatment of metastatic castration-resistant prostate cancer.

  OncoTargets and therapy 20100101

• First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.

  OncoTargets and therapy 20100101

• Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

  Breast cancer research : BCR 20100101

• Challenges in treating older patients with acute myeloid leukemia.

  Journal of oncology 20100101

• The role of glatiramer acetate in the early treatment of multiple sclerosis.

  Neuropsychiatric disease and treatment 20100101

• Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.

  BMC cancer 20100101

• Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines.

  Chinese medicine 20100101

• Angiogenesis inhibitors in the treatment of prostate cancer.

  Journal of hematology & oncology 20100101

• Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

  Drug design, development and therapy 20100101

• Fluorouracil selectively enriches stem-like leukemic cells in a leukemic cell line.

  International journal of biological sciences 20100101

• H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy.

  Journal of nucleic acids 20100101

• Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.

  PloS one 20100101

• Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplantation: a case report.

  Journal of medical case reports 20100101

• Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.

  BMC pharmacology 20100101

• Molecular pathology of retinoblastoma.

  Middle East African journal of ophthalmology 20100101

• Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide.

  Journal of nucleic acids 20100101

• Biclonal follicular lymphoma: histological, clinical and molecular characteristics.

  Pathology 20100101

• Disease-modifying therapies in relapsing-remitting multiple sclerosis.

  Neuropsychiatric disease and treatment 20100101

• Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.

  Therapeutics and clinical risk management 20100101

• Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation.

  PloS one 20100101

• Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

  Journal of oncology 20100101

• Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

  BMC cancer 20100101

• Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

  Advances in hematology 20100101

• A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia.

  BMC cancer 20100101

• Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.

  BMC clinical pharmacology 20100101

• Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution.

  BMC research notes 20100101

• Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

  BMC cancer 20100101

• Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

  BMC neurology 20100101

• NEO adjuvant chemotherapy in breast cancer: What have we learned so far?

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• Secondary acute myeloid leukemia after successful treatment for osteosarcoma.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• Nano to micro delivery systems: targeting angiogenesis in brain tumors.

  Journal of angiogenesis research 20100101

• 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.

  PloS one 20100101

• Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.

  Neuropsychiatric disease and treatment 20100101

• Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes.

  International journal of nanomedicine 20100101

• In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system.

  International journal of nanomedicine 20100101

• Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

  International journal of nanomedicine 20100101

• Targeting the osteosarcoma cancer stem cell.

  Journal of orthopaedic surgery and research 20100101

• A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.

  Genetic vaccines and therapy 20100101

• Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.

  BMC cancer 20100101

• Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.

  Core evidence 20100101

• GADD45β Determines Chemoresistance and Invasive Growth of Side Population Cells of Human Embryonic Carcinoma.

  Stem cells international 20100101

• Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

  Breast cancer research : BCR 20100101

• Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown.

  PloS one 20100101

• Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

  PloS one 20100101

• Dendritic cell-based immunotherapy for prostate cancer.

  Clinical & developmental immunology 20100101

• Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

  Health and quality of life outcomes 20100101

• Selected aspects of the epidemiology of multiple sclerosis in Poland - a multicentre pilot study.

  Neurologia i neurochirurgia polska 20100101

• Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

  BMC cancer 20100101

• Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

  Molecular cancer 20100101

• Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

  BMC cancer 20100101

• New approaches in the management of multiple sclerosis.

  Drug design, development and therapy 20100101

• Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

  PloS one 20100101

• Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

  Clinical interventions in aging 20100101

• A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA.

  Alzheimer's research & therapy 20100101

• Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.

  Journal of experimental & clinical cancer research : CR 20100101

• Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies.

  International journal of nanomedicine 20100101

• Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases.

  BMC urology 20100101

• Rituximab for the treatment of patients with chronic lymphocytic leukemia.

  Cancer management and research 20100101

• Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.

  Cancer management and research 20100101

• Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.

  Cancer management and research 20100101

• Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.

  Advances in pharmacological sciences 20100101

• DNA vaccination: using the patient's immune system to overcome cancer.

  Clinical & developmental immunology 20100101

• Disease modifying agents for multiple sclerosis.

  The open neurology journal 20100101

• Beta-interferons in multiple sclerosis.

  Annals of Indian Academy of Neurology 20100101

• The spectrum of use of rituximab in chronic lymphocytic leukemia.

  OncoTargets and therapy 20100101

• Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy.

  Cell death & disease 20100101

• Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients.

  Mediterranean journal of hematology and infectious diseases 20100101

• Application of new drugs in chronic lymphocytic leukemia.

  Mediterranean journal of hematology and infectious diseases 20100101

• Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry.

  Mediterranean journal of hematology and infectious diseases 20100101

• Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.

  Clinical & developmental immunology 20100101

• Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up.

  Journal of Ayurveda and integrative medicine 20100101

• [Multiple sclerosis: emerging treatments].

  Bulletin de l'Academie nationale de medecine 20100101

• 1,8-Bis(tos-yloxy)-9,10-anthraquinone.

  Acta crystallographica. Section E, Structure reports online 20100101

• Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.

  ClinicoEconomics and outcomes research : CEOR 20100101

• Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.

  Journal of inflammation research 20100101

• New and emerging agents in the management of lipodystrophy in HIV-infected patients.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis.

  Multiple sclerosis international 20100101

• The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies.

  Journal of blood medicine 20100101

• Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.

  Pediatric blood & cancer 20091215

• Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.

  British journal of cancer 20091215

• A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.

  Nanomedicine : nanotechnology, biology, and medicine 20091201

• ABCG2: the key to chemoresistance in cancer stem cells?

  Expert opinion on drug metabolism & toxicology 20091201

• Restoring immune suppression in the multiple sclerosis brain.

  Progress in neurobiology 20091201

• Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.

  Pediatrics 20091201

• Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response.

  Cellular & molecular immunology 20091201

• Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

  Neoplasia (New York, N.Y.) 20091201

• [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].

  Zhongguo shi yan xue ye xue za zhi 20091201

• Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.

  Anticancer research 20091201

• A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and Cisplatin chemotherapy and systemic low-dose infusion of 5-Fluorouracil.

  Gut and liver 20091201

• Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

  British journal of cancer 20091117

• Chemotherapy induces ATP release from tumor cells.

  Cell cycle (Georgetown, Tex.) 20091115

• Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.

  Journal of medicinal chemistry 20091112

• Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

• Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.

  Annals of hematology 20091101

• Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

  Molecular pharmacology 20091101

• Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.

  Experimental hematology 20091101

• Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.

  Current opinion in ophthalmology 20091101

• Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20091101

• Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.

  Leukemia & lymphoma 20091101

• [Rescue treatments for multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20091101

• [Treatment of NMO].

  Rinsho shinkeigaku = Clinical neurology 20091101

• The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.

  Anticancer research 20091101

• Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

  Therapeutic advances in neurological disorders 20091101

• Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

  British journal of cancer 20091020

• Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.

  British journal of cancer 20091020

• Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas.

  British journal of cancer 20091020

• Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan.

  Colloids and surfaces. B, Biointerfaces 20091015

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.

  Journal of medicinal chemistry 20091008

• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

  British journal of cancer 20091006

• Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

  Investigational new drugs 20091001

• Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20091001

• ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.

  Journal of cancer research and clinical oncology 20091001

• B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.

  Clinical neurology and neurosurgery 20091001

• Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.

  Leukemia & lymphoma 20091001

• Lack of ABCG2 expression and side population properties in human pluripotent stem cells.

  Stem cells (Dayton, Ohio) 20091001

• Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response.

  Journal of cellular and molecular medicine 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

  Molecular cancer therapeutics 20091001

• Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.

  Therapeutic drug monitoring 20091001

• Modern concepts in the treatment of chronic lymphocytic leukemia.

  Hematology (Amsterdam, Netherlands) 20091001

• Treatment of multiple sclerosis: role of natalizumab.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

• Mitoxantrone: benefits and risks in multiple sclerosis patients.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

• Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

  Neurology 20090922

• Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.

  The Prostate 20090915

• Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

  British journal of cancer 20090915

• Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.

  Cancer research 20090915

• International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

  Journal of the National Cancer Institute 20090902

• (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

  European journal of nuclear medicine and molecular imaging 20090901

• Radiochemotherapy in the treatment of breast cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20090901

• Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

  Cancer science 20090901

• [Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone].

  Der Urologe. Ausg. A 20090901

• Dose-dependent melanonychia by mitoxantrone.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090901

• ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

  Brain : a journal of neurology 20090901

• Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.

  Leukemia & lymphoma 20090901

• Poly(ethylene glycol)-stabilized silver nanoparticles for bioanalytical applications of SERS spectroscopy.

  The Analyst 20090901

• Long-term outcomes of de novo acute myeloid leukemia in Thai patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090901

• Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090901

• Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.

  Health technology assessment (Winchester, England) 20090901

• Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.

  Leukemia & lymphoma 20090901

• Could stress granules be involved in age-related diseases?

  Aging 20090901

• Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20090901

• C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.

  Bioorganic & medicinal chemistry letters 20090815

• Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090812

• Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.

  Cancer chemotherapy and pharmacology 20090801

• Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.

  Leukemia research 20090801

• A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

  Leukemia 20090801

• Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

  The Journal of pharmacology and experimental therapeutics 20090801

• Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.

  British journal of haematology 20090801

• A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2).

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090801

• Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.

  Oncology reports 20090801

• ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.

  Hematology (Amsterdam, Netherlands) 20090801

• Antitumor potential of three herbal extracts against human oral squamous cell lines.

  Anticancer research 20090801

• Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090801

• [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090801

• Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.

  British journal of cancer 20090721

• Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy.

  The Veterinary record 20090718

• Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.

  Biochemical pharmacology 20090715

• Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

  Bioorganic & medicinal chemistry 20090715

• Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

  Cancer research 20090715

• Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.

  Cancer chemotherapy and pharmacology 20090701

• Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.

  Bone marrow transplantation 20090701

• Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.

  Leukemia research 20090701

• Arginine 383 is a crucial residue in ABCG2 biogenesis.

  Biochimica et biophysica acta 20090701

• Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

  Leukemia & lymphoma 20090701

• Identification of a pancreatic stellate cell population with properties of progenitor cells: new role for stellate cells in the pancreas.

  The Biochemical journal 20090626

• High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.

  Journal of medicinal chemistry 20090625

• Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

  Oncogene 20090618

• Cyclophosphamide therapy in pediatric multiple sclerosis.

  Neurology 20090616

• In vitro and in vivo interaction of moxidectin with BCRP/ABCG2.

  Chemico-biological interactions 20090615

• Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090610

• T-regulatory cell modulation: the future of cancer immunotherapy?

  British journal of cancer 20090602

• Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.

  International journal of cancer 20090601

• What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

  BJU international 20090601

• MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.

  Molecular pharmacology 20090601

• Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

  Pharmacoepidemiology and drug safety 20090601

• DNA damage response as a biomarker in treatment of leukemias.

  Cell cycle (Georgetown, Tex.) 20090601

• Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

  Bioconjugate chemistry 20090601

• Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.

  Puerto Rico health sciences journal 20090601

• A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.

  Journal of Korean medical science 20090601

• A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

  Assay and drug development technologies 20090601

• [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].

  Zhongguo shi yan xue ye xue za zhi 20090601

• Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.

  Chinese journal of integrative medicine 20090601

• Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.

  Journal of chemical biology 20090601

• Pentostatin treatment combinations in chronic lymphocytic leukemia.

  Clinical advances in hematology & oncology : H&O 20090601

• Isolation and identification of a new impurity in mitoxantrone hydrochloride.

  Die Pharmazie 20090601

• Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.

  Ai zheng = Aizheng = Chinese journal of cancer 20090601

• Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair.

  Current genomics 20090601

• Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone).

  Chemistry & biology 20090529

• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.

  British journal of cancer 20090505

• Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

  Cancer gene therapy 20090501

• Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.

  Cancer 20090501

• Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.

  Gynecologic oncology 20090501

• [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].

  Aktuelle Urologie 20090501

• [Stem cell therapy in multiple sclerosis: a clinical update].

  Zeitschrift fur Rheumatologie 20090501

• HIV and anal cancer outcomes: a single institution's experience.

  Diseases of the colon and rectum 20090501

• [Mitoxantrone for the treatment of patients with multiple sclerosis].

  Brain and nerve = Shinkei kenkyu no shinpo 20090501

• Complexation of biologically active aromatic compounds with DNA in the presence of theophylline.

  Journal of biological physics 20090501

• Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines.

  Molecules (Basel, Switzerland) 20090424

• Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

  Blood 20090423

• A structure-based approach to ligand discovery for 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase: a target for antimicrobial therapy.

  Journal of medicinal chemistry 20090423

• Methodological approaches in application of synthetic lethality screening towards anticancer therapy.

  British journal of cancer 20090421

• p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090415

• Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.

  British journal of cancer 20090407

• Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador.

  British journal of cancer 20090407

• Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

  Leukemia research 20090401

• Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.

  Echocardiography (Mount Kisco, N.Y.) 20090401

• Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090401

• The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.

  American journal of hematology 20090401

• Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.

  American journal of hematology 20090401

• Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

  Cancer research 20090401

• CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.

  Electrophoresis 20090401

• Hematology: germinal center or nongerminal center DLBCL?

  Nature reviews. Clinical oncology 20090401

• [Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090401

• Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients.

  International journal of pharmaceutics 20090331

• Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening.

  Proceedings of the National Academy of Sciences of the United States of America 20090324

• PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

  Cell stem cell 20090306

• Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

  Leukemia 20090301

• Identification of a potential 'hotspot' DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.

  Genes, chromosomes & cancer 20090301

• CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.

  Leukemia 20090301

• Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20090301

• DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.

  ChemMedChem 20090301

• Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones.

  Bioorganic & medicinal chemistry 20090301

• Quantitative analysis via Surface Enhanced Raman Scattering from Ag nano-colloids utilizing an oscillating cell and right-angle collection geometry.

  The Analyst 20090301

• Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.

  Molecular cancer therapeutics 20090301

• Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2.

  Biological & pharmaceutical bulletin 20090301

• Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.

  Journal of the National Medical Association 20090301

• How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

  European journal of neurology 20090301

• Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

  European journal of neurology 20090301

• Development of cell-cycle inhibitors for cancer therapy.

  Current oncology (Toronto, Ont.) 20090301

• Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis.

  Clinical therapeutics 20090301

• Quantum-SAR extension of the spectral-SAR algorithm: application to polyphenolic anticancer bioactivity.

  International journal of molecular sciences 20090301

• Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia.

  Journal of hematopathology 20090301

• Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells.

  Biochemical and biophysical research communications 20090227

• Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells.

  British journal of cancer 20090224

• Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.

  International journal of pharmaceutics 20090223

• Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals.

  Cell cycle (Georgetown, Tex.) 20090215

• BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

  British journal of cancer 20090210

• The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.

  Molecular and cellular biochemistry 20090201

• The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

  Oncology reports 20090201

• The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

  Cancer research 20090201

• Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.

  Thrombosis and haemostasis 20090201

• Bendamustine in the treatment of chronic lymphocytic leukemia.

  Expert review of anticancer therapy 20090201

• Concepts of induction and escalation therapy in multiple sclerosis.

  Journal of the neurological sciences 20090201

• Long-term experience with induction treatment regimens in multiple sclerosis.

  Journal of the neurological sciences 20090201

• Immunosuppression followed by immunomodulation.

  Journal of the neurological sciences 20090201

• Reversible foetal cerebral ventriculomegaly and cardiomyopathy under chemotherapy for maternal AML.

  Onkologie 20090201

• Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitro.

  Cancer biotherapy & radiopharmaceuticals 20090201

• [Therapeutic effect and toxicity of compound vincristine liposome on breast cancer in nude mice].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20090201

• Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts).

  Indian journal of anaesthesia 20090201

• Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

  Advanced drug delivery reviews 20090131

• Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).

  Cancer genetics and cytogenetics 20090115

• Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.

  British journal of cancer 20090113

• The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

  Prostate cancer and prostatic diseases 20090101

• A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

  Annals of hematology 20090101

• Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20090101

• Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis.

  Leukemia 20090101

• Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.

  Molecular pharmacology 20090101

• Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.

  European neurology 20090101

• Do estroprogestinic hormones protect against chemotherapy-induced amenorrhea in multiple sclerosis?

  Nature clinical practice. Neurology 20090101

• Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101

• Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.

  Molecular pharmaceutics 20090101

• Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.

  Neoplasia (New York, N.Y.) 20090101

• Anticancer drug-DNA interactions measured using a photoinduced electron-transfer mechanism based on luminescent quantum dots.

  Analytical chemistry 20090101

• Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

  Current eye research 20090101

• An unusual radiologic pattern of cryptogenic organizing pneumonia: diffuse pulmonary nodules in a leukemia patient.

  Korean journal of radiology 20090101

• A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.

  Current medical research and opinion 20090101

• Successfully conservative treatment of large cervical choriocarcinoma with profuse vaginal bleeding.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090101

• Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

  Journal of biomedical science 20090101

• Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model.

  Journal of translational medicine 20090101

• A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study.

  World journal of surgical oncology 20090101

• Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

  Radiation oncology (London, England) 20090101

• Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling.

  BMC public health 20090101

• Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.

  PloS one 20090101

• MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

  Breast cancer research : BCR 20090101

• MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

  BMC cancer 20090101

• HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance.

  Journal of experimental & clinical cancer research : CR 20090101

• Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.

  Therapeutics and clinical risk management 20090101

• Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

  Therapeutics and clinical risk management 20090101

• Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.

  BMC cancer 20090101

• d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis.

  Journal of carcinogenesis 20090101

• Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy.

  European journal of dermatology : EJD 20090101

• A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

  PloS one 20090101

• Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1.

  PloS one 20090101

• Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

  Clinical interventions in aging 20090101

• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

  Trials 20090101

• Anthracycline extravasation injuries: management with dexrazoxane.

  Therapeutics and clinical risk management 20090101

• Primary non-Hodgkin's lymphoma of the infratemporal fossa: a rare case report.

  Head & neck oncology 20090101

• Non-Hodgkin lymphoma response evaluation with MRI texture classification.

  Journal of experimental & clinical cancer research : CR 20090101

• P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

  BMC cancer 20090101

• Breast cancer stem cells: tools and models to rely on.

  BMC cancer 20090101

• The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells.

  Radiation oncology (London, England) 20090101

• A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.

  BMC cancer 20090101

• A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.

  Journal of hematology & oncology 20090101

• H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells.

  PloS one 20090101

• Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases.

  Indian journal of urology : IJU : journal of the Urological Society of India 20090101

• Adjuvant electrochemotherapy in veterinary patients: a model for the planning of future therapies in humans.

  Journal of experimental & clinical cancer research : CR 20090101

• Inhibitory effect of flavonoids on the efflux of N-acetyl 5-aminosalicylic acid intracellularly formed in Caco-2 cells.

  Journal of biomedicine & biotechnology 20090101

• Natalizumab in the treatment of multiple sclerosis.

  Therapeutics and clinical risk management 20090101

• Mitoxantrone therapy for acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis.

  Case reports in medicine 20090101

• Networking of differentially expressed genes in human cancer cells resistant to methotrexate.

  Genome medicine 20090101

• Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity.

  BMC pharmacology 20090101

• Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

  PloS one 20090101

• NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.

  PloS one 20090101

• Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report.

  BMC neurology 20090101

• Image guided dose escalated prostate radiotherapy: still room to improve.

  Radiation oncology (London, England) 20090101

• [Use of mitoxantrone in the treatment of multiple sclerosis].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Alternative splicing and transcriptome profiling of experimental autoimmune encephalomyelitis using genome-wide exon arrays.

  PloS one 20090101

• Gene expression profiles of mouse spermatogenesis during recovery from irradiation.

  Reproductive biology and endocrinology : RB&E 20090101

• iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

  Molecular cancer 20090101

• Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

  Journal of hematology & oncology 20090101

• Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report.

  Cases journal 20090101

• High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.

  International journal of medical sciences 20090101

• Drug-induced hematologic syndromes.

  Advances in hematology 20090101

• Recent developments in multiple sclerosis therapeutics.

  BMC medicine 20090101

• Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

  BMC infectious diseases 20090101

• SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

  Trials 20090101

• Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.

  Health and quality of life outcomes 20090101

• [Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

  Drug design, development and therapy 20090101

• Mucosa associated lymphoid tissue lymphoma of the colon: a case report.

  Cases journal 20090101

• What lies behind serum urate concentration? Insights from genetic and genomic studies.

  Genome medicine 20090101

• Developmental and Reproductive Effects of SE5-OH: An Equol-Rich Soy-Based Ingredient.

  Journal of toxicology 20090101

• Mitroxantrone in multiple sclerosis.

  Neurology India 20090101

• Role of multidrug transporters in neurotherapeutics.

  Annals of Indian Academy of Neurology 20090101

• Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report.

  Cases journal 20090101

• B cells as a target of immune modulation.

  Annals of Indian Academy of Neurology 20090101

• Neuromyelitis optica - an update: 2007-2009.

  Annals of Indian Academy of Neurology 20090101

• Disease-modifying agents in multiple sclerosis.

  Annals of Indian Academy of Neurology 20090101

• The symptomatic management of multiple sclerosis.

  Annals of Indian Academy of Neurology 20090101

• Solid lipid nanoparticles: a modern formulation approach in drug delivery system.

  Indian journal of pharmaceutical sciences 20090101

• Role of bendamustine in the treatment of chronic lymphocytic leukemia.

  OncoTargets and therapy 20090101

• Expanded use of rituximab in the management of non-Hodgkin lymphoma.

  OncoTargets and therapy 20090101

• Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.

  OncoTargets and therapy 20090101

• Bendamustine in the treatment of non-Hodgkin's lymphomas.

  OncoTargets and therapy 20090101

• Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.

  Cancer management and research 20090101

• The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.

  Cancer management and research 20090101

• Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.

  Cancer management and research 20090101

• Multiple sclerosis.

  BMJ clinical evidence 20090101

• Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

  BMJ case reports 20090101

• Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab.

  ClinicoEconomics and outcomes research : CEOR 20090101

• Assessing cost-effectiveness in the management of multiple sclerosis.

  ClinicoEconomics and outcomes research : CEOR 20090101

• Semiconductor quantum dots in chemical sensors and biosensors.

  Sensors (Basel, Switzerland) 20090101

• Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.

  Biochemistry 20081230

• Interaction of mitoxantrone with human serum albumin: spectroscopic and molecular modeling studies.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081218

• Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group.

  British journal of cancer 20081209

• Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

  British journal of cancer 20081209

• A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

  BJU international 20081201

• High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells.

  Biochimica et biophysica acta 20081201

• [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].

  Revue neurologique 20081201

• Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20081201

• Treatment of invasive aspergillosis with nonmyeloablative allogeneic stem cell transplantation: the hunter becomes the hunted.

  American journal of hematology 20081201

• Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.

  The Journal of pharmacy and pharmacology 20081201

• Interactions of mitoxantrone with duplex and triplex DNA studied by electrospray ionization mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20081201

• ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.

  Cancer science 20081201

• Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20081201

• Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.

  PLoS biology 20081201

• Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.

  Annals of surgery 20081201

• Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20081201

• New therapeutical approaches for non muscle invasive bladder cancer.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20081201

• Systems biology: a therapeutic target for tumor therapy.

  Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20081201

• Rituximab in the treatment of non-Hodgkin's lymphoma.

  Biologics : targets & therapy 20081201

• Sorafenib for the treatment of unresectable hepatocellular carcinoma.

  Biologics : targets & therapy 20081201

• Novel microtubule-targeting agents - the epothilones.

  Biologics : targets & therapy 20081201

• Bevacizumab in the treatment of HER2-negative breast cancer.

  Biologics : targets & therapy 20081201

• Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.

  Neurology 20081125

• Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081115

• Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

  Journal of medicinal chemistry 20081113

• Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

  British journal of cancer 20081104

• The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

  Clinical neurology and neurosurgery 20081101

• A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.

  Journal of biomedical materials research. Part A 20081101

• Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20081101

• Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.

  American journal of hematology 20081101

• Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.

  Brain : a journal of neurology 20081101

• Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix.

  Neoplasia (New York, N.Y.) 20081101

• [Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20081101

• [FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures].

  Zhonghua nei ke za zhi 20081101

• [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• Future research directions for the treatment of AML.

  Clinical advances in hematology & oncology : H&O 20081101

• Escalating immunotherapy of multiple sclerosis.

  Therapeutic advances in neurological disorders 20081101

• Docetaxel chemotherapy of Korean patients with hormone- refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel.

  Yonsei medical journal 20081031

• Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.

  Biochemical and biophysical research communications 20081024

• Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

  Blood 20081015

• Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.

  Journal of the neurological sciences 20081015

• Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081001

• Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081001

• Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.

  International journal of pharmaceutics 20081001

• Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.

  International journal of cancer 20081001

• Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.

  Japanese journal of clinical oncology 20081001

• Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.

  Cell cycle (Georgetown, Tex.) 20081001

• [Choice of early and escalation treatment options for multiple sclerosis].

  Der Nervenarzt 20081001

• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

  Cancer research 20081001

• Antipsychotic drugs inhibit the function of breast cancer resistance protein.

  Basic & clinical pharmacology & toxicology 20081001

• Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

  Journal of neurology 20081001

• Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

  Journal of neurology 20081001

• Intrathecal corticosteroids might slow Alzheimer's disease progression.

  Neuropsychiatric disease and treatment 20081001

• Clinical pharmacology.

  Indian journal of pharmacology 20081001

• Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.

  Life sciences 20080926

• Aminoacyl-anthraquinone conjugates as telomerase inhibitors: synthesis, biophysical and biological evaluation.

  Journal of medicinal chemistry 20080925

• Survival from non-Hodgkin lymphoma in England and Wales up to 2001.

  British journal of cancer 20080923

• Intramolecular electron transfer versus substrate oxidation in lactoperoxidase: investigation of radical intermediates by stopped-flow absorption spectrophotometry and (9-285 GHz) electron paramagnetic resonance spectroscopy.

  Biochemistry 20080916

• Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080902

• Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

  British journal of cancer 20080902

• Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20080901

• The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.

  Cell death and differentiation 20080901

• Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.

  International journal of pharmaceutics 20080901

• Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

  Annals of hematology 20080901

• Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

  Nature clinical practice. Oncology 20080901

• Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.

  Current opinion in supportive and palliative care 20080901

• Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080901

• Induction vs. escalating therapy in multiple sclerosis: practical implications.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080901

• Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

  Current medical research and opinion 20080901

• Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

  Current neurology and neuroscience reports 20080901

• Presence or absence of a gallate moiety on catechins affects their cellular transport.

  The Journal of pharmacy and pharmacology 20080901

• Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.

  Molecular cancer therapeutics 20080901

• Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.

  Molecular cancer therapeutics 20080901

• Clinical investigations in aggressive non-Hodgkin lymphoma.

  Clinical advances in hematology & oncology : H&O 20080901

• Mitoxantrone-related acute leukemia in two MS patients.

  Acta neurologica Belgica 20080901

• Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

  Biologics : targets & therapy 20080901

• Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.

  Biologics : targets & therapy 20080901

• NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

  The Journal of biological chemistry 20080829

• Perspective on 'Chemotherapy for advanced prostate cancer: 25 years later': is it a mirage or an oasis?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820

• A role for topoisomerase II alpha in the formation of radiation-induced chromatid breaks.

  British journal of cancer 20080819

• ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin.

  Journal of immunology (Baltimore, Md. : 1950) 20080815

• Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080807

• The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.

  BJU international 20080805

• Resistance to chemotherapy: new treatments and novel insights into an old problem.

  British journal of cancer 20080805

• Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.

  Neurology 20080805

• Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.

  BJU international 20080801

• The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.

  Acta neurologica Scandinavica 20080801

• Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080801

• Azathioprine in multiple sclerosis.

  Mini reviews in medicinal chemistry 20080801

• [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].

  Ai zheng = Aizheng = Chinese journal of cancer 20080801

• [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20080801

• Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.

  Leukemia & lymphoma 20080801

• Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.

  Current oncology (Toronto, Ont.) 20080801

• [Study on ratiometric determination of peroxynitrite and its scavenger based on synchronous fluorescence spectroscopy].

  Guang pu xue yu guang pu fen xi = Guang pu 20080801

• Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.

  Therapeutics and clinical risk management 20080801

• Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: perspective on mechanisms of action.

  Journal of neuroimmunology 20080715

• A mesoporous silica thin film as uptake host for guest molecules with retarded release kinetics.

  Chemphyschem : a European journal of chemical physics and physical chemistry 20080714

• EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

  British journal of cancer 20080708

• The postchemotherapy PSA surge syndrome.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.

  Carcinogenesis 20080701

• Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.

  Molecular pharmacology 20080701

• Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.

  Anti-cancer drugs 20080701

• Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.

  Journal of medicinal chemistry 20080626

• Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.

  British journal of cancer 20080617

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Polymeric micelles in oral chemotherapy.

  Journal of controlled release : official journal of the Controlled Release Society 20080604

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).

  European journal of haematology 20080601

• Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.

  Cancer treatment reviews 20080601

• Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080601

• Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20080601

• Getting specific: monoclonal antibodies in multiple sclerosis.

  The Lancet. Neurology 20080601

• CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.

  Oncology reports 20080601

• Effective multiple sclerosis management through improved patient assessment.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080601

• Newly developed multiple myeloma in a patient with primary T-cell lymphoma of bone.

  Journal of Korean medical science 20080601

• Pharmacologic management of multiple sclerosis.

  Urologic nursing 20080601

• Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080601

• Comparative studies of glatiramer acetate and interferon beta.

  International MS journal 20080601

• Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.

  Journal of cellular biochemistry 20080515

• Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.

  Mutation research 20080510

• Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

  Journal of the National Cancer Institute 20080507

• Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

  British journal of cancer 20080506

• [Chemotherapy for prostate cancer].

  Presse medicale (Paris, France : 1983) 20080501

• Secondary chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia.

  Pathologie-biologie 20080501

• Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development.

  Pharmaceutical research 20080501

• Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

  Journal of neuro-oncology 20080501

• A theoretical study on interactions between mitoxantrone as an anticancer drug and DNA: application in drug design.

  Chemical biology & drug design 20080501

• Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.

  British journal of haematology 20080501

• Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080501

• A vault ribonucleoprotein particle exhibiting 39-fold dihedral symmetry.

  Acta crystallographica. Section D, Biological crystallography 20080501

• Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

  Cancer genetics and cytogenetics 20080415

• Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.

  Journal of pharmaceutical sciences 20080401

• Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved.

  Toxicology in vitro : an international journal published in association with BIBRA 20080401

• The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

  Bioorganic & medicinal chemistry 20080401

• Ex vivo simulation of the action of antileukemia drugs by measuring apoptosis-related mRNA in blood.

  Clinical chemistry 20080401

• Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.

  European journal of neurology 20080401

• Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

  The Lancet. Oncology 20080401

• Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

  European journal of neurology 20080401

• Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080401

• Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.

  Journal of clinical and experimental hematopathology : JCEH 20080401

• Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture.

  Journal of the Chinese Medical Association : JCMA 20080401

• Biweekly docetaxel-containing chemotherapy may be the optimal schedule.

  Anti-cancer drugs 20080401

• Role of phosphodiesterase 5 in synaptic plasticity and memory.

  Neuropsychiatric disease and treatment 20080401

• Treating refractory leukemias in childhood, role of clofarabine.

  Therapeutics and clinical risk management 20080401

• Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.

  Journal of the neurological sciences 20080315

• Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.

  British journal of cancer 20080311

• A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.

  British journal of cancer 20080311

• Acute myelogenous leukemia associated with Ollier disease.

  Pediatric blood & cancer 20080301

• Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.

  Leukemia research 20080301

• Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080301

• Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.

  Journal of clinical immunology 20080301

• Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080301

• Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

  Leukemia & lymphoma 20080301

• Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

  Leukemia & lymphoma 20080301

• Evaluation of the antiangiogenic potential of AQ4N.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• Combination therapies in multiple sclerosis.

  Journal of neurology 20080301

• Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue.

  Molecular cancer therapeutics 20080301

• Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations.

  The Journal of veterinary medical science 20080301

• Severe bladder contracture leading to cystectomy after intravesical mitoxantrone chemotherapy.

  Anti-cancer drugs 20080301

• 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.

  British journal of cancer 20080226

• Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.

  Cancer letters 20080218

• WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.

  Biochemical pharmacology 20080215

• A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.

  Cancer 20080215

• The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.

  The Journal of biological chemistry 20080208

• Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

  Blood 20080201

• Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

  Molecular pharmacology 20080201

• Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.

  BJU international 20080201

• Spectroelectrochemistry of the redox activation of anti-cancer drug mitoxantrone.

  Bioelectrochemistry (Amsterdam, Netherlands) 20080201

• Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

  European journal of haematology 20080201

• Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

  The Lancet. Neurology 20080201

• High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

  Haematologica 20080201

• Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma.

  Leukemia & lymphoma 20080201

• Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.

  Cancer research 20080201

• ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition.

  Cancer research 20080201

• Pulmonary complications of novel antineoplastic agents for solid tumors.

  Chest 20080201

• A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction.

  Molecular cancer therapeutics 20080201

• Cyclic metabolites: chemical and biological considerations.

  Current drug metabolism 20080201

• Second-line chemotherapy for advanced hormone-refractory prostate cancer.

  Clinical advances in hematology & oncology : H&O 20080201

• Mitoxantrone: multiple sclerosis: too many serious adverse effects.

  Prescrire international 20080201

• [The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080201

• Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015.

  Therapeutics and clinical risk management 20080201

• Surface-enhanced Raman spectroscopy substrates created via electron beam lithography and nanotransfer printing.

  ACS nano 20080201

• Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade.

  British journal of cancer 20080129

• Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080120

• A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer.

  British journal of cancer 20080115

• Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.

  British journal of cancer 20080115

• Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.

  Cancer genetics and cytogenetics 20080115

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• Sheddable coatings for long-circulating nanoparticles.

  Pharmaceutical research 20080101

• Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.

  American journal of hematology 20080101

• Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

  Journal of neurology, neurosurgery, and psychiatry 20080101

• Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.

  Bioorganic & medicinal chemistry 20080101

• Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone.

  Journal of neurology 20080101

• Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101

• Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.

  Acta oncologica (Stockholm, Sweden) 20080101

• Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment.

  Haematologica 20080101

• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study.

  Trials 20080101

• Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.

  Leukemia & lymphoma 20080101

• Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.

  Current topics in microbiology and immunology 20080101

• Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma.

  BMC neuroscience 20080101

• Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).

  BMC cancer 20080101

• Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.

  Hemoglobin 20080101

• Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

  Current oncology (Toronto, Ont.) 20080101

• The impact of the human DNA topoisomerase II C-terminal domain on activity.

  PloS one 20080101

• [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].

  Revue neurologique 20080101

• Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling.

  Cancer cell international 20080101

• ABCG2: structure, function and role in drug response.

  Expert opinion on drug metabolism & toxicology 20080101

• Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.

  BMC cancer 20080101

• Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.

  BMC cancer 20080101

• A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy.

  International journal of medical sciences 20080101

• Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy).

  In vivo (Athens, Greece) 20080101

• Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

  PloS one 20080101

• Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation.

  PloS one 20080101

• A role for surgery in primary pancreatic B-cell lymphoma: a case report.

  Journal of medical case reports 20080101

• Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

  Molecular cancer 20080101

• Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.

  Genome biology 20080101

• Genotyping panel for assessing response to cancer chemotherapy.

  BMC medical genomics 20080101

• Localized small-bowel infarction caused by Aspergillus during chemotherapy for acute myeloid leukemia: report of a case.

  Surgery today 20080101

• Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.

  Journal of experimental & clinical cancer research : CR 20080101

• Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.

  Urologic oncology 20080101

• Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

  PloS one 20080101

• A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.

  BMC cancer 20080101

• Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.

  Anticancer research 20080101

• PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis.

  PPAR research 20080101

• Substantial activity of mitoxantrone and paclitaxel in a heavily pre-treated metastatic bladder cancer patient.

  The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 20080101

• Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

  Journal of translational medicine 20080101

• Novel therapies in genitourinary cancer: an update.

  Journal of hematology & oncology 20080101

• Interactions between antitumor drugs and vault RNA.

  Nucleic acids symposium series (2004) 20080101

• Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.

  Journal of experimental & clinical cancer research : CR 20080101

• An in silico approach to map the binding site of doxorubicin on hemoglobin.

  Bioinformation 20080101

• Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus.

  Clinical and experimental rheumatology 20080101

• Novel therapies in breast cancer: what is new from ASCO 2008.

  Journal of hematology & oncology 20080101

• Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.

  American journal of clinical dermatology 20080101

• Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.

  Journal of experimental & clinical cancer research : CR 20080101

• Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.

  BMC cancer 20080101

• High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer.

  Anticancer research 20080101

• Effect of differentiating agents (all-trans retinoic acid and phorbol 12-myristate 13-acetate) on drug sensitivity of HL60 and NB4 cells in vitro.

  Folia histochemica et cytobiologica 20080101

• Copper transport systems are involved in multidrug resistance and drug transport.

  Current medicinal chemistry 20080101

• Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.

  Acta biochimica Polonica 20080101

• Evolving perspectives of the role of novel agents in androgen-independent prostate cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20080101

• Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

  Gene regulation and systems biology 20080101

• Acute thrombosis in superior mesenteric artery as first symptom in a AML patient.

  International journal of general medicine 20080101

• Quality of life measurement in bone metastases: A literature review.

  Journal of pain research 20080101

• Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review.

  The Pan African medical journal 20080101

• Frontiers of cancer care in Asia-Pacific region: cancer care in Australia.

  Biomedical imaging and intervention journal 20080101

• Experimental antioxidant therapy in ataxia telangiectasia.

  Clinical medicine. Oncology 20080101

• A case of successful intrapleural chemotherapy with Cisplatin plus cytarabine for intractable malignant pleural effusion.

  Yonsei medical journal 20071231

• Quantitative online detection of low-concentrated drugs via a SERS microfluidic system.

  Chemphyschem : a European journal of chemical physics and physical chemistry 20071221

• Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.

  British journal of cancer 20071217

• Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.

  British journal of cancer 20071217

• Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071210

• Effect of excipients on breast cancer resistance protein substrate uptake activity.

  Journal of controlled release : official journal of the Controlled Release Society 20071204

• A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

  British journal of cancer 20071203

• Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

  Annals of hematology 20071201

• Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

  Leukemia 20071201

• Chemotherapy for the treatment of hormone-refractory prostate cancer.

  International journal of clinical practice 20071201

• In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

  British journal of pharmacology 20071201

• Integration of 18O labeling and solution isoelectric focusing in a shotgun analysis of mitochondrial proteins.

  Journal of proteome research 20071201

• Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.

  Journal of immunology (Baltimore, Md. : 1950) 20071201

• Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis.

  Experimental dermatology 20071201

• The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.

  Molecular cancer therapeutics 20071201

• Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

  Journal of natural products 20071201

• New inhibitors of ABCG2 identified by high-throughput screening.

  Molecular cancer therapeutics 20071201

• Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.

  Molecular cancer therapeutics 20071201

• Multiple sclerosis: interferon beta for some serious forms.

  Prescrire international 20071201

• [Nursing care of patients with basic multiple sclerosis therapy: preventing relapses].

  Pflege Zeitschrift 20071201

• Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles.

  International journal of nanomedicine 20071201

• Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

  International journal of nanomedicine 20071201

• Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.

  Clinical interventions in aging 20071201

• Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.

  Growth factors (Chur, Switzerland) 20071201

• ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.

  International journal of cardiology 20071130

• American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• Synthesis and biological evaluation of novel cytotoxic azanaphthoquinone annelated pyrrolo oximes.

  Bioorganic & medicinal chemistry letters 20071115

• Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

  Cancer research 20071115

• Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.

  British journal of cancer 20071105

• Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

  Cancer chemotherapy and pharmacology 20071101

• The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.

  Differentiation; research in biological diversity 20071101

• The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

  British journal of pharmacology 20071101

• Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.

  Current medical research and opinion 20071101

• Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.

  Leukemia & lymphoma 20071101

• Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up.

  European journal of neurology 20071101

• A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.

  Leukemia & lymphoma 20071101

• [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].

  Journal francais d'ophtalmologie 20071101

• Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).

  International journal of hematology 20071101

• Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.

  Chinese medical journal 20071020

• Resonance Rayleigh scattering spectra for studying the interaction of anthracycline antineoplastic antibiotics with some anionic surfactants and their analytical applications.

  Analytica chimica acta 20071003

• Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071001

• Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.

  Leukemia 20071001

• A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).

  The Journal of pharmacology and experimental therapeutics 20071001

• Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.

  Japanese journal of clinical oncology 20071001

• Immunosuppressive agents in multiple sclerosis.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20071001

• Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.

  Expert opinion on investigational drugs 20071001

• Multiplexed microfluidic surface-enhanced Raman spectroscopy.

  Applied spectroscopy 20071001

• Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report.

  The Journal of reproductive medicine 20071001

• Liposomal drug delivery systems: an update review.

  Current drug delivery 20071001

• Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.

  Therapeutics and clinical risk management 20071001

• Bortezomib for the treatment of mantle cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

  British journal of cancer 20070911

• Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.

  Journal of cellular biochemistry 20070901

• Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070901

• Preclinical antitumor activity of the oral platinum analog satraplatin.

  Cancer chemotherapy and pharmacology 20070901

• Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20070901

• Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.

  Cancer science 20070901

• [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].

  Der Nervenarzt 20070901

• Generation and identification of reactive metabolites by electrochemistry and immobilized enzymes coupled on-line to liquid chromatography/mass spectrometry.

  Analytical chemistry 20070901

• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.

  Haematologica 20070901

• Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.

  Oncology (Williston Park, N.Y.) 20070901

• [A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].

  Hinyokika kiyo. Acta urologica Japonica 20070901

• Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.

  Experimental oncology 20070901

• [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070901

• Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.

  Biologics : targets & therapy 20070901

• Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.

  British journal of cancer 20070820

• Immunosuppression: promises and failures.

  Journal of the neurological sciences 20070815

• Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.

  Journal of the neurological sciences 20070815

• Multiple sclerosis.

  BMJ clinical evidence 20070815

• Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

  Pediatric blood & cancer 20070801

• Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.

  European urology 20070801

• Paraneoplastic Sweet's syndrome and the pathergy phenomenon.

  Annals of hematology 20070801

• Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.

  Annals of surgical oncology 20070801

• On the origin of the decrease in stability of the DNA hairpin d(GCGAAGC) on complexation with aromatic drugs.

  Biophysical chemistry 20070801

• Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

  Leukemia 20070801

• Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

  Cancer 20070801

• Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.

  Nature clinical practice. Oncology 20070801

• Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.

  The Journal of dermatology 20070801

• Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.

  Leukemia & lymphoma 20070801

• Leukaemia due to mitoxantrone.

  Prescrire international 20070801

• The renaissance of fixed dose combinations: Combivir.

  Therapeutics and clinical risk management 20070801

• Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.

  Cancer chemotherapy and pharmacology 20070701

• Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

  European journal of nuclear medicine and molecular imaging 20070701

• Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis.

  The Biochemical journal 20070701

• Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems.

  Pharmaceutical research 20070701

• The effect of short-term intensive chemotherapy on reactivation of tuberculosis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

  Leukemia & lymphoma 20070701

• Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.

  Leukemia & lymphoma 20070701

• [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20070701

• [Prostate cancer and chemotherapy].

  Bulletin du cancer 20070701

• [Metastatic prostate cancer treatment in the elderly].

  Bulletin du cancer 20070701

• Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.

  Journal of the Mississippi State Medical Association 20070701

• C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

  Biochemical pharmacology 20070630

• Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.

  Bioorganic & medicinal chemistry 20070615

• Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.

  Cancer research 20070615

• Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.

  British journal of cancer 20070604

• Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.

  Investigational new drugs 20070601

• Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.

  The Journal of pharmacology and experimental therapeutics 20070601

• Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.

  Annals of hematology 20070601

• The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.

  Leukemia 20070601

• Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.

  Expert opinion on pharmacotherapy 20070601

• Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070601

• Multiple sclerosis in Pakistan.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070601

• Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

  Current medical research and opinion 20070601

• Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20070601

• Natalizumab: A new treatment for relapsing remitting multiple sclerosis.

  Therapeutics and clinical risk management 20070601

• An overview of the clinical use of ondansetron in preschool age children.

  Therapeutics and clinical risk management 20070601

• Energy transfer to analyse membrane-integrated mitoxantrone in BCRP-overexpressed cells.

  Journal of photochemistry and photobiology. B, Biology 20070525

• Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

  British journal of cancer 20070521

• [Advances in the treatment of multiple sclerosis?].

  MMW Fortschritte der Medizin 20070521

• Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070520

• Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

  Journal of immunology (Baltimore, Md. : 1950) 20070515

• Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.

  Cancer research 20070515

• Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.

  Neurology 20070508

• The first case of mitoxantrone exposure in early pregnancy.

  Neurotoxicology 20070501

• Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.

  International journal of cancer 20070501

• Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines.

  Drug metabolism and disposition: the biological fate of chemicals 20070501

• Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.

  Leukemia 20070501

• Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

  Cancer chemotherapy and pharmacology 20070501

• CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.

  Annals of hematology 20070501

• Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry.

  Journal of mass spectrometry : JMS 20070501

• Current treatment options in multiple sclerosis.

  Current treatment options in neurology 20070501

• Disseminated cutaneous Fusarium moniliforme infections in a leukemic child.

  International journal of dermatology 20070501

• Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.

  Leukemia & lymphoma 20070501

• Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.

  Haematologica 20070501

• Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.

  Molecular cancer therapeutics 20070501

• The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.

  Transplantation proceedings 20070501

• A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.

  Biochemistry 20070424

• Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism.

  British journal of cancer 20070423

• Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.

  Bioorganic & medicinal chemistry 20070415

• Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

  Cancer 20070415

• Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line.

  Cancer research 20070415

• Design, synthesis, and evaluation of the antiproliferative activity of a series of novel fused xanthenone aminoderivatives in human breast cancer cells.

  Journal of medicinal chemistry 20070405

• Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• MEK-ERK is involved in SUMO-1 foci formation on apoptosis.

  Cancer science 20070401

• QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.

  Anti-cancer drugs 20070401

• [Preparation of liposome entrapped vincristine sulfate and mitoxantrone chlorhydric acid].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20070401

• Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.

  The Korean journal of laboratory medicine 20070401

• A case of lineage switch from acute lymphoblastic leukemia to acute myeloid leukemia.

  The Korean journal of laboratory medicine 20070401

• Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.

  Movement disorders : official journal of the Movement Disorder Society 20070315

• Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.

  Pediatric blood & cancer 20070301

• Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.

  European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20070301

• Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

  Leukemia 20070301

• Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.

  Leukemia 20070301

• Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.

  Leukemia 20070301

• Synthesis and in vitro cytotoxicity evaluation of novel naphthindolizinedione derivatives.

  Archiv der Pharmazie 20070301

• ABCG2: determining its relevance in clinical drug resistance.

  Cancer metastasis reviews 20070301

• Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

  Haematologica 20070301

• Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.

  Haematologica 20070301

• The safety profile of cyclophosphamide in multiple sclerosis therapy.

  Expert opinion on drug safety 20070301

• [Hodgkin lymphoma in Chile: experience of the national adult cancer program].

  Revista medica de Chile 20070301

• Gene expressions associated with chemosensitivity in human hepatoma cells.

  Hepato-gastroenterology 20070301

• Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.

  Iranian journal of immunology : IJI 20070301

• Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.

  Yonsei medical journal 20070227

• Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

  Blood 20070215

• Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.

  British journal of cancer 20070212

• Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

  Investigational new drugs 20070201

• Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.

  Molecular and cellular biochemistry 20070201

• Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.

  Drug metabolism and disposition: the biological fate of chemicals 20070201

• Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.

  Anti-cancer drugs 20070201

• Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

  Journal of neurology, neurosurgery, and psychiatry 20070201

• Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• Synthesis and human telomerase inhibition of a series of regioisomeric disubstituted amidoanthraquinones.

  Chemical & pharmaceutical bulletin 20070201

• 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis.

  Pediatric neurology 20070201

• [Mandibular chloroma].

  Revue de stomatologie et de chirurgie maxillo-faciale 20070201

• Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.

  Cell cycle (Georgetown, Tex.) 20070201

• [A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• Use of rituximab in patients with follicular lymphoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070201

• New multidisciplinary prostate bone metastases clinic: first of its kind in Canada.

  Current oncology (Toronto, Ont.) 20070201

• Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.

  British journal of cancer 20070129

• Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.

  British journal of cancer 20070129

• Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070120

• Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.

  Journal of the National Cancer Institute 20070117

• Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.

  Cancer letters 20070108

• Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.

  Cancer chemotherapy and pharmacology 20070101

• In silico prediction of pregnane X receptor activators by machine learning approaches.

  Molecular pharmacology 20070101

• Current indications for chemotherapy in prostate cancer patients.

  European urology 20070101

• Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

  Molecular pharmacology 20070101

• Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.

  Cancer science 20070101

• Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

  Cardiovascular and interventional radiology 20070101

• Late relapses in acute promyelocytic leukaemia.

  Acta haematologica 20070101

• Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion.

  The Journal of pathology 20070101

• A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

  Health technology assessment (Winchester, England) 20070101

• Calreticulin exposure dictates the immunogenicity of cancer cell death.

  Nature medicine 20070101

• Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.

  Archives of Iranian medicine 20070101

• [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Novel expressed sequences identified in a model of androgen independent prostate cancer.

  BMC genomics 20070101

• The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds.

  Current drug metabolism 20070101

• Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features.

  Anticancer research 20070101

• Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.

  Molecular pharmaceutics 20070101

• Analysis of NAMCS data for multiple sclerosis, 1998-2004.

  BMC medicine 20070101

• Immunomodulatory treatment of multiple sclerosis in Norway.

  Acta neurologica Scandinavica. Supplementum 20070101

• Molecular and cellular characterization of ABCG2 in the prostate.

  BMC urology 20070101

• Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.

  Cancer journal (Sudbury, Mass.) 20070101

• The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.

  Asian Pacific journal of cancer prevention : APJCP 20070101

• N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma.

  Molecular cancer 20070101

• Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides.

  Chinese medicine 20070101

• New paradigms for advanced prostate cancer.

  Reviews in urology 20070101

• [Optimization of treatment options through a multidisciplinary approach for advanced hormone refractory prostate carcinoma].

  Tumori 20070101

• HER-2/neu diagnostics in breast cancer.

  Breast cancer research : BCR 20070101

• Curcumin as chemosensitizer.

  Advances in experimental medicine and biology 20070101

• Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.

  Drugs & aging 20070101

• Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma.

  Anticancer research 20070101

• ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke.

  BMC cell biology 20070101

• Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.

  Anticancer research 20070101

• External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

  BMC cancer 20070101

• Resistance-associated signatures in breast cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

• Optical method for real-time monitoring of drug concentrations facilitates the development of novel methods for drug delivery to brain tissue.

  Journal of biomedical optics 20070101

• A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

  BMC cancer 20070101

• Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.

  PloS one 20070101

• Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

  Anticancer research 20070101

• Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate.

  PloS one 20070101

• [The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].

  Terapevticheskii arkhiv 20070101

• Therapeutic options for hormone-refractory prostate cancer in 2007.

  Urologic oncology 20070101

• Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.

  Journal of translational medicine 20070101

• Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes.

  Acta haematologica 20070101

• Do general dimensions of quality of life add clinical value to symptom data?

  Journal of the National Cancer Institute. Monographs 20070101

• Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers.

  European journal of gynaecological oncology 20070101

• Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3H3 mouse fibroblasts.

  Anticancer research 20070101

• Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

  Urologia internationalis 20070101

• Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.

  Genome biology 20070101

• Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.

  Journal of managed care pharmacy : JMCP 20070101

• Urachal mucinous adenocarcinoma: a case report.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070101

• Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.

  Oncology research 20070101

• Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer.

  Tumori 20070101

• Update in palliative management of hormone refractory cancer of prostate.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Chemotherapy for hormone-resistant prostate cancer: Where are we today?

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• New therapeutic targets in the treatment of prostate cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value.

  Core evidence 20070101

• Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

  Blood 20061215

• Comment on electron transfer vs differential decay in irradiated DNA.

  The journal of physical chemistry. B 20061214

• Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice.

  Pharmacological research 20061201

• Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.

  Leukemia 20061201

• The case for early chemotherapy for the treatment of metastatic disease.

  The Journal of urology 20061201

• In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.

  Oncology reports 20061201

• [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

  Der Nervenarzt 20061201

• Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.

  Expert review of neurotherapeutics 20061201

• Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.

  Haematologica 20061201

• [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20061201

• [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201

• Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.

  Neurosurgery 20061201

• [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].

  Yao xue xue bao = Acta pharmaceutica Sinica 20061201

• New methods for direct delivery of chemotherapy for treating brain tumors.

  The Yale journal of biology and medicine 20061201

• [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

  Ideggyogyaszati szemle 20061120

• Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.

  Journal of medicinal chemistry 20061116

• Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents.

  Cancer research 20061115

• In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.

  European journal of pharmacology 20061107

• Synthesis and calculated properties of some 1,4-bis(amino)anthracene-9,10-diones.

  Organic & biomolecular chemistry 20061107

• Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.

  Molecular and cellular biology 20061101

• Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.

  British journal of pharmacology 20061101

• Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

  International journal of oncology 20061101

• The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20061101

• Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20061101

• Treatment-related myelodysplasia following fludarabine combination chemotherapy.

  Haematologica 20061101

• Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.

  Archives of neurology 20061101

• [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20061101

• High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin's lymphoma: an eight-year experience.

  Yonsei medical journal 20061031

• Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.

  British journal of cancer 20061023

• Chemotherapy for hormone-refractory prostate cancer.

  The Cochrane database of systematic reviews 20061018

• Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

  British journal of cancer 20061009

• Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).

  Annals of hematology 20061001

• Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20061001

• Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.

  Leukemia 20061001

• Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study.

  Nature clinical practice. Oncology 20061001

• Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.

  Molecular cancer therapeutics 20061001

• [Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061001

• New directions in the treatment of mantle cell lymphoma: an overview.

  Clinical lymphoma & myeloma 20061001

• Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060920

• Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.

  Cancer chemotherapy and pharmacology 20060901

• Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.

  Cancer science 20060901

• Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.

  Leukemia 20060901

• Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.

  Cancer 20060901

• A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study.

  European journal of cancer (Oxford, England : 1990) 20060901

• Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery: in regards to Toledano et al. (Int J Radiat Oncol Biol Phys 2006;65:324-332).

  International journal of radiation oncology, biology, physics 20060901

• Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

  Journal of neurology 20060901

• Fertility in patients with multiple sclerosis: current knowledge and future perspectives.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20060901

• Anti-cancer activities of 1,4-naphthoquinones: a QSAR study.

  Anti-cancer agents in medicinal chemistry 20060901

• Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.

  Leukemia & lymphoma 20060901

• Glatiramer in the treatment of multiple sclerosis.

  International journal of nanomedicine 20060901

• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.

  International journal of nanomedicine 20060901

• A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.

  British journal of cancer 20060821

• Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells.

  The Journal of biological chemistry 20060818

• The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.

  Cancer 20060815

• Postirradiation electron transfer vs differential radical decay in X-irradiated DNA and its mixtures with additives. Electron spin resonance spectroscopy in LiBr glass at low temperatures.

  The journal of physical chemistry. B 20060803

• Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.

  Journal of neurology 20060801

• Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

  Current opinion in pharmacology 20060801

• Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis.

  Journal of cellular physiology 20060801

• Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.

  Cancer biology & therapy 20060801

• Purification of breast cancer resistance protein ABCG2 and role of arginine-482.

  Cellular and molecular life sciences : CMLS 20060801

• Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: Comparison with mitoxantrone.

  Cell biology international 20060801

• Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.

  Neurosurgery 20060801

• [Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line].

  Zhongguo shi yan xue ye xue za zhi 20060801

• Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.

  Molecular cancer therapeutics 20060801

• High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

  Leukemia & lymphoma 20060801

• Important differences between topoisomerase-I and -II targeting agents.

  Cancer biology & therapy 20060801

• The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.

  Biochemistry 20060725

• Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.

  Blood 20060715

• Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).

  Blood 20060715

• In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.

  International journal of cancer 20060715

• Metabolites of ginsenosides as novel BCRP inhibitors.

  Biochemical and biophysical research communications 20060714

• Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.

  Leukemia research 20060701

• Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.

  Molecular pharmacology 20060701

• How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

  Annals of neurology 20060701

• Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

  Archives of neurology 20060701

• Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation.

  Acta histochemica et cytochemica 20060701

• Early onset cardiotoxicity associated with mitoxantrone in patients with multiple sclerosis.

  Neurosciences (Riyadh, Saudi Arabia) 20060701

• [Drug therapy in multiple sclerosis].

  La Revue du praticien 20060630

• Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

  British journal of cancer 20060619

• Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.

  British journal of cancer 20060605

• Gene expression profiles of two accelerations in a CML patient.

  Leukemia research 20060601

• The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?

  International journal of cancer 20060601

• Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.

  International journal of radiation oncology, biology, physics 20060601

• Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

  Cancer 20060601

• CD24 Ala/Val polymorphism and multiple sclerosis.

  Journal of neuroimmunology 20060601

• [Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20060601

• Immunological studies of mitoxantrone in primary progressive MS.

  Journal of neuroimmunology 20060601

• Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.

  American journal of hematology 20060601

• Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.

  BJU international 20060601

• Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.

  Journal of materials science. Materials in medicine 20060601

• Optimization of preparation of DHAQ-loaded PEG-PLGA-PEG nonaparticles using central composite design.

  Journal of materials science. Materials in medicine 20060601

• Telomerase activity is not a key determinant of sensitivity to standard cytotoxic drugs in human esophageal carcinoma cell lines.

  Anti-cancer drugs 20060601

• Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma.

  British journal of haematology 20060601

• Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601

• Multidrug resistance and stem cells in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20060601

• Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.

  Urology 20060601

• Current chemotherapeutic approaches for androgen-independent prostate cancer.

  Current opinion in investigational drugs (London, England : 2000) 20060601

• [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20060601

• The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.

  FEBS letters 20060529

• Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus.

  British journal of cancer 20060522

• [Practical advice for a safe, effective and well tolerated therapy of multiple sclerosis].

  MMW Fortschritte der Medizin 20060515

• Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.

  Neurology 20060509

• Dramatical improvement of chemoresistant bone lymphoma with rituximab.

  Clinical rheumatology 20060501

• Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells.

  American journal of physiology. Endocrinology and metabolism 20060501

• Targeting cancer cells: magnetic nanoparticles as drug carriers.

  European biophysics journal : EBJ 20060501

• Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060501

• Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).

  Lung cancer (Amsterdam, Netherlands) 20060501

• Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.

  The Journal of urology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.

  Haematologica 20060501

• Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia.

  American journal of hematology 20060501

• Gender change and its impact on the course of multiple sclerosis.

  Acta neurologica Scandinavica 20060501

• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  The Urologic clinics of North America 20060501

• Therapeutic potential of iron chelators in diseases associated with iron mismanagement.

  The Journal of pharmacy and pharmacology 20060501

• [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• Extreme Hodgkin's lymphoma: current problem areas.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• [Therapeutic options for hormone-refractory prostate cancer].

  Der Urologe. Ausg. A 20060501

• [Preparation and characterization of transfersomes of three drugs in vitro].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20060501

• Treatment of relapsed acute myeloid leukaemia.

  Reviews on recent clinical trials 20060501

• Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.

  Biochemistry 20060425

• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

  Journal of the National Cancer Institute 20060419

• Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.

  British journal of cancer 20060410

• Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.

  International journal of cancer 20060401

• Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.

  Molecular pharmacology 20060401

• Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.

  The Journal of urology 20060401

• Chemotherapy for high-risk localized prostate cancer.

  BJU international 20060401

• Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060401

• Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues.

  Chemical & pharmaceutical bulletin 20060401

• [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs].

  Zhongguo shi yan xue ye xue za zhi 20060401

• Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.

  Molecular cancer therapeutics 20060401

• Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.

  Archives of Iranian medicine 20060401

• [A case of secondary malignant lymphoma of the urinary bladder].

  Hinyokika kiyo. Acta urologica Japonica 20060401

• Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.

  Leukemia & lymphoma 20060401

• The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.

  Leukemia & lymphoma 20060401

• Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.

  Leukemia & lymphoma 20060401

• Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

  Journal of chemotherapy (Florence, Italy) 20060401

• Management of worsening multiple sclerosis with mitoxantrone: a review.

  Clinical therapeutics 20060401

• Treatment of acute myeloid leukemia in older adults: time to reflect?

  Leukemia & lymphoma 20060401

• Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration.

  British journal of cancer 20060327

• A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.

  British journal of cancer 20060327

• PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.

  Chemico-biological interactions 20060325

• A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.

  International journal of radiation oncology, biology, physics 20060315

• Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.

  Cancer research 20060315

• Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

  Cancer letters 20060308

• Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.

  Leukemia & lymphoma 20060301

• Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.

  British journal of haematology 20060301

• First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

  Cancer 20060301

• Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.

  British journal of haematology 20060301

• A high-throughput cell-based assay for inhibitors of ABCG2 activity.

  Journal of biomolecular screening 20060301

• The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

  Expert opinion on drug safety 20060301

• Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.

  Expert review of neurotherapeutics 20060301

• Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.

  Cancer science 20060301

• Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.

  Clinical and experimental medicine 20060301

• Intensive immunosuppression in multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20060301

• Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.

  British journal of cancer 20060227

• Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.

  Cancer 20060215

• Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.

  European journal of pharmacology 20060215

• Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.

  Journal of the American Veterinary Medical Association 20060215

• Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

  Cancer research 20060215

• Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.

  World journal of gastroenterology 20060214

• Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.

  British journal of cancer 20060213

• Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

  British journal of cancer 20060213

• Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.

  Leukemia research 20060201

• The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20060201

• Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.

  Urology 20060201

• [Mitoxantrone in the treatment of multiple sclerosis: risks and benefits].

  Revue neurologique 20060201

• [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

  Revue neurologique 20060201

• [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].

  Revue neurologique 20060201

• [Investigation on the properties of mitoxantrone-insulin conjugates lyophilized powder].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20060201

• Doxetaxel: new indication. Prostate cancer: a few more weeks.

  Prescrire international 20060201

• [Acute airway obstruction during chemotherapy-induced agranulocytosis with fever].

  Revue de pneumologie clinique 20060201

• Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.

  International journal of pharmaceutics 20060113

• Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. I: Formulation and in vitro characterization.

  International journal of pharmaceutics 20060113

• The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis.

  Leukemia research 20060101

• Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.

  Cell death and differentiation 20060101

• Therapeutic role of mitoxantrone in multiple sclerosis.

  Pharmacology & therapeutics 20060101

• Antitumor triptycene analogs induce a rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria.

  International journal of oncology 20060101

• Non-Hodgkin disease in beta-thalassemia major.

  American journal of hematology 20060101

• Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.

  Annals of neurology 20060101

• A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.

  Journal of translational medicine 20060101

• Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.

  BMC cancer 20060101

• Multiple sclerosis mimics.

  Advances in neurology 20060101

• Mitoxantrone in multiple sclerosis.

  Advances in neurology 20060101

• Enhancement of sodium fluoride-induced cell death by centrifugal force.

  In vivo (Athens, Greece) 20060101

• Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

  Cleveland Clinic journal of medicine 20060101

• Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

  Clinical and experimental pharmacology & physiology 20060101

• Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.

  Placenta 20060101

• Merkel cell carcinoma.

  World journal of surgical oncology 20060101

• [Tumor cell targetability of folate receptor-mediated mitoxantrone albumin nanoparticles].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060101

• Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system.

  Journal of experimental therapeutics & oncology 20060101

• Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

  International journal of immunopathology and pharmacology 20060101

• Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone.

  Anticancer research 20060101

• Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.

  BMC cancer 20060101

• Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.

  BMC cancer 20060101

• Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases.

  BMC cancer 20060101

• Cancer and kinases: reports from the front line.

  Genome biology 20060101

• Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.

  Urologic oncology 20060101

• Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.

  BMC cancer 20060101

• Skin involvement in Hodgkin's disease.

  Cancer investigation 20060101

• Mitoxantrone changes spectrin-aminophospholipid interactions.

  Molecular membrane biology 20060101

• The changing pattern of management for hormone-refractory, metastatic prostate cancer.

  Prostate cancer and prostatic diseases 20060101

• Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.

  BMC cancer 20060101

• Heart failure induced by non-cardiac drugs.

  Drug safety 20060101

• Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): A phase II study (GOAM 01.01 study).

  Anticancer research 20060101

• Clinical management of women with metastatic breast cancer: a descriptive study according to age group.

  BMC cancer 20060101

• Gastro-intestinal symptoms as clinical manifestation of peritoneal and retroperitoneal spread of an invasive lobular breast cancer: report of a case and review of the literature.

  BMC cancer 20060101

• Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.

  Acta bio-medica : Atenei Parmensis 20060101

• Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.

  Cancer investigation 20060101

• [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].

  Terapevticheskii arkhiv 20060101

• Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.

  Clinical neuropharmacology 20060101

• In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.

  Neuroimmunomodulation 20060101

• The treatment of hormone-refractory prostate cancer: docetaxel and beyond.

  Reviews in urology 20060101

• Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

  Molecular cancer 20060101

• Measuring proliferation in breast cancer: practicalities and applications.

  Breast cancer research : BCR 20060101

• Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.

  Anticancer research 20060101

• Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.

  Oncology 20060101

• Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells.

  Oncology 20060101

• FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.

  Core evidence 20060101

• Mitoxantrone treatment of multiple sclerosis: safety considerations.

  Neurology 20051227

• A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

  Cancer 20051215

• The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

  British journal of cancer 20051212

• Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.

  Leukemia 20051201

• Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.

  Leukemia 20051201

• Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.

  Apoptosis : an international journal on programmed cell death 20051201

• BCRP transports dipyridamole and is inhibited by calcium channel blockers.

  Pharmaceutical research 20051201

• Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials.

  Leukemia 20051201

• [Therapy of hormone-refractory prostate cancer].

  Der Urologe. Ausg. A 20051201

• Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.

  Cancer research 20051201

• Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.

  Haematologica 20051201

• [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• Therapeutic options in androgen-independent prostate cancer: building on docetaxel.

  BJU international 20051201

• Induction versus escalation therapy.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20051201

• Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.

  Haematologica 20051201

• Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*.

  Veterinary and comparative oncology 20051201

• Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.

  British journal of cancer 20051128

• Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

  Oncogene 20051117

• Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).

  Journal of medicinal chemistry 20051117

• Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.

  Bioorganic & medicinal chemistry letters 20051115

• Management of advanced prostate cancer after first-line chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051110

• [What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].

  MMW Fortschritte der Medizin 20051110

• Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.

  The Journal of biological chemistry 20051104

• Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis.

  Journal of neuroimmunology 20051101

• Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.

  Journal of neuroimmunology 20051101

• Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20051101

• Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

  The Journal of urology 20051101

• [Treatment options for hormone-refractory prostate cancer].

  Der Urologe. Ausg. A 20051101

• Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

  Journal of neuro-oncology 20051101

• Mitoxantrone in the treatment of multiple sclerosis.

  International MS journal 20051101

• [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20051101

• Drug insight: using monoclonal antibodies to treat multiple sclerosis.

  Nature clinical practice. Neurology 20051101

• [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].

  Nederlands tijdschrift voor geneeskunde 20051029

• Mitoxantrone for multiple sclerosis.

  The Cochrane database of systematic reviews 20051019

• Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

  Journal of neurology 20051001

• Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

  Cancer chemotherapy and pharmacology 20051001

• High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.

  Annals of hematology 20051001

• Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

  Leukemia research 20051001

• Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

  Oncology reports 20051001

• Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones.

  Anti-cancer drugs 20051001

• Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

  British journal of haematology 20051001

• Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation.

  Bioscience, biotechnology, and biochemistry 20051001

• Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.

  Scandinavian journal of gastroenterology 20051001

• [Prostate cancer: update].

  Bulletin du cancer 20051001

• Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.

  British journal of cancer 20050919

• Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.

  Neurology 20050913

• A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

  Annals of hematology 20050901

• Hetero-association of anticancer antibiotics in aqueous solution: NMR and molecular mechanics analysis.

  Biophysical chemistry 20050901

• High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050901

• Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract.

  Biochemical pharmacology 20050901

• Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

  Leukemia research 20050901

• Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.

  Bone marrow transplantation 20050901

• Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells.

  Oncology reports 20050901

• A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

  International journal of radiation oncology, biology, physics 20050901

• [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].

  Aktuelle Urologie 20050901

• Clinical implications of neuropathological findings in multiple sclerosis.

  Journal of neurology 20050901

• Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20050901

• [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050901

• Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.

  British journal of cancer 20050822

• Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20050818

• Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.

  Biochemical pharmacology 20050815

• Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.

  Annals of hematology 20050801

• A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.

  Cancer chemotherapy and pharmacology 20050801

• Single nucleotide polymorphisms modify the transporter activity of ABCG2.

  Cancer chemotherapy and pharmacology 20050801

• Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).

  Genes, chromosomes & cancer 20050801

• Interaction of anticancer drug mitoxantrone with DNA analyzed by electrochemical and spectroscopic methods.

  Biophysical chemistry 20050801

• Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.

  Molecular pharmacology 20050801

• A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.

  Bone marrow transplantation 20050801

• Cold stress-induced pea DNA helicase 47 is homologous to eIF4A and inhibited by DNA-interacting ligands.

  Archives of biochemistry and biophysics 20050801

• Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.

  Investigational new drugs 20050801

• Preliminary investigation of mitoxantrone coating on stent-grafts to inhibit neointimal proliferation.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20050801

• The role of pixantrone in the treatment of non-Hodgkin's lymphoma.

  Expert opinion on investigational drugs 20050801

• Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

  Cancer research 20050801

• The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  Urology 20050801

• Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.

  Cancer science 20050801

• [Therapy of hormone refractory prostate cancer: new standards, new trends].

  Aktuelle Urologie 20050801

• Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.

  Internal medicine journal 20050801

• Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review.

  Pharmacotherapy 20050801

• Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.

  Statistics in medicine 20050730

• [Multiple sclerosis--update].

  Praxis 20050727

• Combined effects of GSTP1 and MRP1 in melanoma drug resistance.

  British journal of cancer 20050725

• Effects of peroxidase substrates on the Amplex red/peroxidase assay: antioxidant properties of anthracyclines.

  Analytical biochemistry 20050715

• Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.

  Cancer 20050715

• Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.

  Cancer genetics and cytogenetics 20050715

• Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

  British journal of cancer 20050711

• Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

  British journal of cancer 20050711

• Modulation of breast cancer resistance protein mediated atypical multidrug resistance using RNA interference delivered by adenovirus.

  Chinese medical journal 20050705

• [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies].

  HNO 20050701

• [Magnetic drug targeting. New paths for the local concentration of drugs for head and neck cancer].

  HNO 20050701

• Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism.

  Biochemical pharmacology 20050701

• Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.

  Internal medicine journal 20050701

• Prolonging survival in prostate cancer: chemotherapy will have an important role.

  BJU international 20050701

• Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome.

  American journal of hematology 20050701

• Article on mitoxantrone-induced extravasation raised useful questions.

  Oncology nursing forum 20050701

• Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.

  Leukemia & lymphoma 20050701

• Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.

  Leukemia & lymphoma 20050701

• Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.

  Leukemia & lymphoma 20050701

• Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.

  Leukemia & lymphoma 20050701

• Extranodal mantle cell lymphoma in a prolapsed ileostomy stump.

  British journal of haematology 20050701

• Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer.

  Lancet (London, England) 20050701

• [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia].

  Zhonghua nei ke za zhi 20050701

• Changing the way we think about chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Promoted electron transfer of mitoxantrone binding with DNA by cytochrome c.

  Biochemical and biophysical research communications 20050617

• Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

  Blood 20050615

• Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

  Blood 20050615

• Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.

  British journal of cancer 20050606

• Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.

  British journal of cancer 20050606

• Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.

  Annals of hematology 20050601

• Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.

  Leukemia 20050601

• [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].

  Der Nervenarzt 20050601

• Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.

  Leukemia 20050601

• High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.

  American journal of clinical oncology 20050601

• Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.

  Cancer research 20050601

• Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.

  Urology 20050601

• Future directions in the treatment of androgen-independent prostate cancer.

  Urology 20050601

• An interdisciplinary approach to treating prostate cancer.

  Urology 20050601

• High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an 'Intergruppo Italiano Linfomi' randomized trial.

  Haematologica 20050601

• A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20050601

• [Structure charateristics of mitoxantrone transforsomes].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20050601

• Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.

  Leukemia & lymphoma 20050601

• [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20050601

• Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients.

  Arquivos de neuro-psiquiatria 20050601

• Acute myeloid leukaemia induced by mitoxantrone: case report.

  Arquivos de neuro-psiquiatria 20050601

• Docetaxel for the treatment of prostate cancer.

  Future oncology (London, England) 20050601

• Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• The application of enhanced parallel gatekeeping strategies.

  Statistics in medicine 20050515

• [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].

  Zhonghua yi xue za zhi 20050511

• A rapid isocratic high-performance liquid chromatography method for determination of cholesterol and 1,2-dioleoyl-sn-glycero-3-phosphocholine in liposome-based drug formulations.

  Journal of chromatography. A 20050506

• The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.

  Mutation research 20050502

• Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

  Blood 20050501

• Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).

  Drug metabolism and disposition: the biological fate of chemicals 20050501

• Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.

  Cancer chemotherapy and pharmacology 20050501

• Therapeutic approaches to combating lipoatrophy: do they work?

  The Journal of antimicrobial chemotherapy 20050501

• Update in the management of patients with hormone-refractory prostate cancer.

  Current opinion in urology 20050501

• Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.

  Journal of neuroimmunology 20050501

• Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.

  Current oncology reports 20050501

• Chemotherapy agents and timing of chemotherapy in prostate cancer management.

  Current urology reports 20050501

• Immunosuppressive therapy in multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20050501

• Local drug delivery in recurrent malignant gliomas.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20050501

• The current role of chemotherapy in metastatic hormone-refractory prostate cancer.

  Urology 20050501

• Knee arthritis as a rare inaugural manifestation of adult leukemia.

  Rheumatology international 20050501

• A practical approach to immunomodulatory therapy for multiple sclerosis.

  Physical medicine and rehabilitation clinics of North America 20050501

• [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].

  Bulletin du cancer 20050501

• Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.

  Expert review of neurotherapeutics 20050501

• Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.

  Blood 20050415

• DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

  The New England journal of medicine 20050414

• Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.

  Annals of hematology 20050401

• Expression and function of ABCB1 and ABCG2 in human placental tissue.

  Drug metabolism and disposition: the biological fate of chemicals 20050401

• Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.

  Molecular pharmacology 20050401

• Changes in adsorption and permeability of mitoxantrone on plasma membrane of BCRP/MXR resistant cells.

  Biochemical and biophysical research communications 20050401

• In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.

  Anti-cancer drugs 20050401

• Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.

  Journal of cell science 20050401

• Multiple bilateral parotid sialoliths in a patient with mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the salivary glands.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20050401

• Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA.

  Journal of neurochemistry 20050401

• LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.

  European journal of haematology 20050401

• Molecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies.

  European journal of medicinal chemistry 20050401

• Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

  Cancer research 20050401

• Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone.

  Journal of chemotherapy (Florence, Italy) 20050401

• Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

  Journal of neuro-oncology 20050401

• Which drug combination for hormone-refractory prostate cancer?

  Expert opinion on pharmacotherapy 20050401

• Recent progress in management of advanced prostate cancer.

  Oncology (Williston Park, N.Y.) 20050401

• Novel therapeutic approaches to advanced prostate cancer.

  Clinical advances in hematology & oncology : H&O 20050401

• Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

  Journal of medicinal chemistry 20050324

• Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.

  Cancer 20050315

• Cyclosporin A is a broad-spectrum multidrug resistance modulator.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.

  Molecular pharmacology 20050301

• Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.

  Leukemia & lymphoma 20050301

• Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.

  Leukemia & lymphoma 20050301

• Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant.

  Leukemia & lymphoma 20050301

• Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.

  Cancer 20050301

• Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.

  Cancer 20050301

• Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones.

  Bioorganic & medicinal chemistry 20050301

• Anti-trypanosomal activities of DNA topoisomerase inhibitors.

  Acta tropica 20050301

• Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.

  European journal of cancer (Oxford, England : 1990) 20050301

• Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.

  British journal of haematology 20050301

• [Current and new therapeutic strategies in acute myeloid leukemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Toxicity of the topoisomerase II inhibitors.

  Expert opinion on drug safety 20050301

• Role of the breast cancer resistance protein (ABCG2) in drug transport.

  The AAPS journal 20050301

• [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050301

• A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.

  Cancer 20050215

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

  The Journal of biological chemistry 20050211

• Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis.

  Rheumatology (Oxford, England) 20050201

• The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.

  Annals of hematology 20050201

• Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20050201

• Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.

  Onkologie 20050201

• Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.

  Onkologie 20050201

• Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

  Biochimica et biophysica acta 20050201

• The role of mitoxantrone in the treatment of indolent lymphomas.

  The oncologist 20050201

• Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.

  Molecular cancer therapeutics 20050201

• [Chemotherapy for prostate cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20050201

• New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

  Expert review of anticancer therapy 20050201

• Myeloid sarcoma occurring in the maxillary gingiva: a case without leukemic manifestations.

  International journal of hematology 20050201

• Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.

  International journal of hematology 20050201

• Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.

  The Canadian journal of urology 20050201

• Lymphoma: diagnosis, staging, natural history, and treatment strategies.

  Seminars in oncology 20050201

• [Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20050201

• Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

  Nature clinical practice. Oncology 20050201

• Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

  Nature clinical practice. Oncology 20050201

• Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.

  Future oncology (London, England) 20050201

• Evolving treatment strategies for myeloma.

  British journal of cancer 20050131

• Exploring the role of different drug transport routes in permeability screening.

  Journal of medicinal chemistry 20050127

• Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.

  British journal of cancer 20050117

• Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.

  British journal of cancer 20050117

• The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer.

  British journal of cancer 20050117

• Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.

  Cancer research 20050115

• Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo.

  The Journal of biological chemistry 20050114

• Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.

  The Journal of pharmacology and experimental therapeutics 20050101

• Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

  The Journal of pharmacology and experimental therapeutics 20050101

• Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.

  Cancer gene therapy 20050101

• Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.

  Biochemical pharmacology 20050101

• Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

  Clinical and experimental immunology 20050101

• Induction chemotherapy for acute myelogenous leukemia.

  Current hematology reports 20050101

• High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

  European journal of cancer (Oxford, England : 1990) 20050101

• Changes in leukemic cell nuclei revealed by differential scanning calorimetry.

  Leukemia & lymphoma 20050101

• A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050101

• [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos.

  The Mount Sinai journal of medicine, New York 20050101

• Mitoxantrone-induced extravasation.

  Oncology nursing forum 20050101

• Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.

  Methods in enzymology 20050101

• US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

  CNS drugs 20050101

• Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells.

  Cellular oncology : the official journal of the International Society for Cellular Oncology 20050101

• Preparation, characterization, and stability of liposome-based formulations of mitoxantrone.

  Drug development and industrial pharmacy 20050101

• Acute demyelination: an insight into the effect of mitoxantrone on CNS lesions.

  Journal of neuroradiology. Journal de neuroradiologie 20050101

• Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model.

  Anticancer research 20050101

• Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.

  Neoplasma 20050101

• Primary progressive multiple sclerosis : current and future treatment options.

  CNS drugs 20050101

• Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.

  BMC cancer 20050101

• ATP-binding cassette (ABC) transporters in normal and pathological lung.

  Respiratory research 20050101

• Case reports: mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma.

  Journal of drugs in dermatology : JDD 20050101

• Methylxanthines (caffeine, pentoxifylline and theophylline) decrease the mutagenic effect of daunomycin, doxorubicin and mitoxantrone.

  Acta biochimica Polonica 20050101

• Mitoxantrone therapy in rapidly worsening multiple sclerosis.

  Bratislavske lekarske listy 20050101

• Cancer cell adaptation to chemotherapy.

  BMC cancer 20050101

• Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine.

  Cancer cell international 20050101

• Gene expression profiling in chemoresistant variants of three cell lines of different origin.

  Anticancer research 20050101

• Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.

  European neurology 20050101

• Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.

  Oncology 20050101

• Anthracyclines.

  Cancer chemotherapy and biological response modifiers 20050101

• Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of high-dose chemotherapy for breast cancer patients.

  International journal of technology assessment in health care 20050101

• Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.

  Neoplasma 20050101

• Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.

  Neoplasma 20050101

• [Chemotherapy of hormone-resistent cancer of the prostate].

  Urologiia (Moscow, Russia : 1999) 20050101

• Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

  BMC cancer 20050101

• Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.

  BMC infectious diseases 20050101

• ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

  Cancer cell international 20050101

• Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20050101

• Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance.

  Journal of proteome research 20050101

• [A structural and thermodynamic analysis of novatrone and flavin mononucleotide heteroassociation in aqueous solution by 1H NMR spectroscopy].

  Bioorganicheskaia khimiia 20050101

• Docetaxel in hormone-refractory metastatic prostate cancer.

  Drugs 20050101

• Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia.

  Urologic oncology 20050101

• Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases.

  Anticancer research 20050101

• Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.

  Anticancer research 20050101

• Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells.

  Journal of proteome research 20050101

• Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.

  Roczniki Akademii Medycznej w Bialymstoku (1995) 20050101

• Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.

  The oncologist 20050101

• [Headache as 'sentinel' symptom in personnel involved in the preparation and administration of antineoplastic drugs].

  Giornale italiano di medicina del lavoro ed ergonomia 20050101

• [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050101

• Mechanism of action of mitoxantrone.

  Neurology 20041228

• Review of mitoxantrone in the treatment of multiple sclerosis.

  Neurology 20041228

• Mitoxantrone for multiple sclerosis in clinical practice.

  Neurology 20041228

• Mitoxantrone treatment of multiple sclerosis: safety considerations.

  Neurology 20041228

• Identifying and treating patients with suboptimal responses.

  Neurology 20041228

• Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis.

  Neurology 20041228

• Current approved options for treating patients with multiple sclerosis.

  Neurology 20041228

• Synthesis and biological evaluation of new 1,5-diazaanthraquinones with cytotoxic activity.

  Bioorganic & medicinal chemistry 20041215

• Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.

  Neurology 20041214

• Strategies for managing the side effects of treatments for multiple sclerosis.

  Neurology 20041214

• Multidrug transporter activity in lymphocytes.

  British journal of pharmacology 20041201

• Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives.

  Bioorganic & medicinal chemistry 20041201

• Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.

  International journal of radiation oncology, biology, physics 20041201

• Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.

  Leukemia & lymphoma 20041201

• [Chemotherapy for hepatocellular carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041201

• Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

  Molecular cancer therapeutics 20041201

• [Biodistribution of N-(2-hydroxypropyl) methacrylamide copolymer-bound mitoxantrone in mice bearing Ehrlich solid tumor].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20041201

• Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport.

  Pharmaceutical research 20041201

• Multiple sclerosis.

  Clinical evidence 20041201

• A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells.

  Oncogene 20041125

• Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.

  Oncogene 20041125

• [Immunomodulatory therapy in multiple sclerosis].

  Ideggyogyaszati szemle 20041120

• The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

  Blood 20041115

• Synthesis and biological evaluation of new derivatives of emodin.

  Bioorganic & medicinal chemistry 20041115

• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  Blood 20041101

• Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.

  Leukemia & lymphoma 20041101

• Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.

  Bone marrow transplantation 20041101

• Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041101

• Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.

  British journal of haematology 20041101

• Effects of anticancer chemotherapeutic drugs on the acetylcholine receptor-operated potassium current in guinea pig atrial myocytes.

  Basic & clinical pharmacology & toxicology 20041101

• [Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20041101

• In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells.

  Journal of microencapsulation 20041101

• Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.

  British journal of cancer 20041018

• Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.

  British journal of cancer 20041018

• Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.

  British journal of cancer 20041018

• Antitumour antibiotic containing regimens for metastatic breast cancer.

  The Cochrane database of systematic reviews 20041018

• Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.

  Journal of medicinal chemistry 20041007

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  The New England journal of medicine 20041007

• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  The New England journal of medicine 20041007

• Pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates. Synthesis, DNA binding and cytotoxicity.

  Bioorganic & medicinal chemistry letters 20041004

• Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

  British journal of cancer 20041004

• Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

  Leukemia research 20041001

• Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.

  Leukemia & lymphoma 20041001

• Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.

  Expert opinion on pharmacotherapy 20041001

• [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].

  Ai zheng = Aizheng = Chinese journal of cancer 20041001

• Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

  Molecular cancer therapeutics 20041001

• [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20041001

• [Clinical study on mitoxantrone contained regimen for treatment of newly diagnosed childhood acute lymphoblastic leukemia].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20041001

• Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.

  Oncogene 20040916

• Is there a role for chemotherapy in prostate cancer?

  British journal of cancer 20040913

• Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!

  British journal of cancer 20040913

• Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.

  International journal of cancer 20040910

• Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.

  The Biochemical journal 20040901

• Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.

  Leukemia 20040901

• The effectiveness and practicality of immunosuppressive drugs.

  International MS journal 20040901

• Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture.

  Cancer research 20040901

• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  Molecular cancer therapeutics 20040901

• Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

  Clinical prostate cancer 20040901

• [Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].

  Der Urologe. Ausg. A 20040901

• A nurse-led, patient-centred mitoxantrone service in neurology.

  British journal of nursing (Mark Allen Publishing) 20040901

• Cytochrome P450 CYP1B1 activity in renal cell carcinoma.

  British journal of cancer 20040831

• Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).

  British journal of cancer 20040816

• In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

  Blood 20040815

• Immunosuppressive treatment in multiple sclerosis.

  Journal of the neurological sciences 20040815

• Mechanisms of mitoxantrone in multiple sclerosis--what is known?

  Journal of the neurological sciences 20040815

• Rationale for the use of mitoxantrone in multiple sclerosis.

  Journal of the neurological sciences 20040815

• The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.

  Journal of the neurological sciences 20040815

• Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience.

  Journal of the neurological sciences 20040815

• Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.

  Journal of the neurological sciences 20040815

• Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.

  Journal of the neurological sciences 20040815

• New immunosuppressants with potential implication in multiple sclerosis.

  Journal of the neurological sciences 20040815

• Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.

  Neurology 20040810

• Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s).

  Journal of neurochemistry 20040801

• Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives.

  Farmaco (Societa chimica italiana : 1989) 20040801

• Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

  Journal of neuroimmunology 20040801

• Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.

  Journal of Korean medical science 20040801

• Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040801

• Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040801

• Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.

  Haematologica 20040801

• Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.

  Haematologica 20040801

• Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.

  International journal of hematology 20040801

• [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040801

• Mutational analysis of ABCG2: role of the GXXXG motif.

  Biochemistry 20040727

• Surface-enhanced Raman scattering reveals adsorption of mitoxantrone on plasma membrane of living cells.

  Biochemical and biophysical research communications 20040723

• Synthesis of 1-(omega-aminoalkyl)naphthoindolediones with antiproliferative properties.

  Bioorganic & medicinal chemistry 20040715

• Multiple sclerosis: management issues during pregnancy.

  European journal of obstetrics, gynecology, and reproductive biology 20040715

• Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature.

  Annals of hematology 20040701

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.

  Leukemia 20040701

• Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040701

• Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.

  Leukemia 20040701

• Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.

  Haematologica 20040701

• Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

  Gynecologic oncology 20040701

• [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• IgD kappa myeloma: a new case.

  Joint, bone, spine : revue du rhumatisme 20040701

• Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.

  Pharmaceutical research 20040701

• Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

  Journal of neuro-oncology 20040701

• [Experimental study of sensitivity to chemotherapeutic agents for human endometrial carcinoma cell line].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040701

• Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus.

  Leukemia & lymphoma 20040701

• Presentation of extramedullary acute myelogenous leukemia as bilateral testicular masses: response to non-myeloablative allogeneic transplantation.

  Leukemia & lymphoma 20040701

• Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.

  Canadian journal of physiology and pharmacology 20040701

• High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615

• Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.

  Cancer 20040615

• Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.

  Cancer research 20040615

• Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells.

  British journal of cancer 20040614

• Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.

  British journal of cancer 20040614

• Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells.

  Bone marrow transplantation 20040601

• A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

  Leukemia research 20040601

• Treatment of a well differentiated pulmonary adenocarcinoma in a cat by pneumonectomy and adjuvant mitoxantrone chemotherapy.

  Journal of feline medicine and surgery 20040601

• Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.

  International journal of oncology 20040601

• Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

  Journal of neuroimmunology 20040601

• Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20040601

• Are statins a treatment option for multiple sclerosis?

  The Lancet. Neurology 20040601

• Health outcomes in multiple sclerosis.

  Current opinion in neurology 20040601

• Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Non-specific immunosuppressants in the treatment of multiple sclerosis.

  Clinical neurology and neurosurgery 20040601

• Small-molecule anthracene-induced cytotoxicity and induction of apoptosis through generation of reactive oxygen species.

  Biological & pharmaceutical bulletin 20040601

• Effect of drugs in secondary disease progression in patients with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040601

• Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040601

• [Chemotherapy of the hormone-refractory prostate cancer].

  Aktuelle Urologie 20040601

• Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient.

  Journal of neurology 20040601

• A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.

  Japanese journal of clinical oncology 20040601

• Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.

  Leukemia & lymphoma 20040601

• A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.

  Hematological oncology 20040601

• Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.

  The New England journal of medicine 20040520

• Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.

  Cancer 20040515

• Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.

  The Journal of biological chemistry 20040507

• Economic burden of acute myeloid leukemia: a literature review.

  Cancer treatment reviews 20040501

• Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

  Cancer chemotherapy and pharmacology 20040501

• Unusual case of subcutaneous panniculitis-like T-cell lymphoma.

  The Australasian journal of dermatology 20040501

• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

  Leukemia research 20040501

• Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.

  Biochemical pharmacology 20040501

• The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.

  Experimental cell research 20040501

• Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

  Molecular pharmacology 20040501

• Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

  Cancer research 20040501

• Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20040501

• Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

  Haematologica 20040501

• Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.

  International journal of hematology 20040501

• Pulmonary infiltrates during chemotherapy-induced febrile neutropenia: incidence, patterns and outcomes.

  JPMA. The Journal of the Pakistan Medical Association 20040501

• Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.

  Leukemia & lymphoma 20040501

• Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20040501

• [Selective tumor-accumulation of HPMA copolymer-mitoxantrone conjugates].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040501

• Disease-modifying drugs for the early treatment of multiple sclerosis.

  Expert review of neurotherapeutics 20040501

• A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

  The Journal of biological chemistry 20040430

• Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

  AIDS (London, England) 20040430

• Interaction of the breast cancer resistance protein with plant polyphenols.

  Biochemical and biophysical research communications 20040423

• Methylation analysis of the glypican 3 gene in embryonal tumours.

  British journal of cancer 20040419

• Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

  British journal of cancer 20040405

• Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.

  British journal of cancer 20040405

• Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin.

  The Journal of biological chemistry 20040402

• Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.

  The Prostate 20040401

• Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20040401

• Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature.

  Journal of Korean medical science 20040401

• A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.

  Expert opinion on pharmacotherapy 20040401

• Novel therapeutic strategies for androgen-independent prostate cancer: an update.

  Seminars in oncology 20040401

• Breast cancer resistance protein (BCRP) in acute leukemia.

  Leukemia & lymphoma 20040401

• Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.

  Leukemia & lymphoma 20040401

• [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040401

• Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.

  Clinical advances in hematology & oncology : H&O 20040401

• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

  International journal of cancer 20040320

• Subcellular localization of the camptothecin analogues, topotecan and gimatecan.

  Biochemical pharmacology 20040315

• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040315

• Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.

  Oncology reports 20040301

• The study of mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons: comparison with cyclophosphamide.

  Xenotransplantation 20040301

• Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.

  British journal of haematology 20040301

• Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.

  European journal of cancer (Oxford, England : 1990) 20040301

• VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

• Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.

  Anti-cancer drugs 20040301

• Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells.

  Anti-cancer drugs 20040301

• Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.

  Auris, nasus, larynx 20040301

• [Primary studies on synthesis and properties of mitoxantrone-insulin conjugates].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20040301

• Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.

  Cancer research 20040215

• Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040215

• [Multiple sclerosis (MS), an inflammatory or degenerative disease?].

  Presse medicale (Paris, France : 1983) 20040214

• [Aggressive multiple sclerosis. Definition and specific therapeutic indication].

  Presse medicale (Paris, France : 1983) 20040214

• Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

  Cancer chemotherapy and pharmacology 20040201

• Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma.

  Langenbeck's archives of surgery 20040201

• Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.

  American journal of clinical oncology 20040201

• Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.

  American journal of clinical oncology 20040201

• Gastrointestinal stromal tumours (Br J Surg 2003; 90: 1178-1186).

  The British journal of surgery 20040201

• Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040201

• Urinary immunocytology for primary bladder B cell lymphoma.

  Urology 20040201

• Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.

  British journal of haematology 20040201

• [Docetaxel and prostate cancer].

  Bulletin du cancer 20040201

• [Radiation and concomitant chemotherapy after surgery for breast cancer].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20040201

• Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.

  Oncogene 20040129

• Suppressing immunity in advancing MS: too much too late, or too late for much?

  Neurology 20040127

• A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.

  Blood 20040115

• Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

  British journal of cancer 20040112

• Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.

  Leukemia 20040101

• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

  International journal of cancer 20040101

• Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.

  Leukemia research 20040101

• The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.

  Clinical and experimental immunology 20040101

• VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines.

  Chemical research in toxicology 20040101

• Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.

  HIV medicine 20040101

• Direct oxidation of 2',7'-dichlorodihydrofluorescein by pyocyanin and other redox-active compounds independent of reactive oxygen species production.

  Free radical biology & medicine 20040101

• Retraction: acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.

  The Annals of pharmacotherapy 20040101

• Treatment of Marburg variant multiple sclerosis with mitoxantrone.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20040101

• Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.

  Current medicinal chemistry. Anti-cancer agents 20040101

• Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

  Molecular cancer research : MCR 20040101

• Pleurodesis for malignant pleural effusions.

  The Cochrane database of systematic reviews 20040101

• [Report of two cases with germinoma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].

  No shinkei geka. Neurological surgery 20040101

• [Antitumor activity of mitoxantrone-nanosphere against murine liver tumor H22].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20040101

• Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.

  Prostate cancer and prostatic diseases 20040101

• Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.

  Journal of the American Animal Hospital Association 20040101

• Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.

  Leukemia & lymphoma 20040101

• Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Use of fludarabine in the treatment of acute myeloid leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Mitoxantrone: a review of its use in multiple sclerosis.

  CNS drugs 20040101

• Maintenance therapy in childhood acute myeloid leukemia.

  Annals of hematology 20040101

• Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor.

  Oncology 20040101

• Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.

  World journal of surgical oncology 20040101

• Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.

  Urologia internationalis 20040101

• A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.

  Journal of gastroenterology 20040101

• [Drug-induced heart failure (excluding that caused by anthracyclines)].

  Therapie 20040101

• Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

  Oncology research 20040101

• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer.

  World journal of surgical oncology 20040101

• Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.

  Acta oncologica (Stockholm, Sweden) 20040101

• Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line.

  Journal of proteome research 20040101

• Management of secondary-progressive multiple sclerosis.

  CNS drugs 20040101

• Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy.

  Health and quality of life outcomes 20040101

• Intravenous immunoglobulin and mitoxantrone stop the progression of secondary progressive multiple sclerosis in a patient with interferon intolerance.

  Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20040101

• Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.

  Anticancer research 20040101

• Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.

  Cancer investigation 20040101

• The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.

  BMC cancer 20040101

• Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.

  BMC pharmacology 20040101

• Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.

  Medical oncology (Northwood, London, England) 20040101

• 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.

  Cancer detection and prevention 20040101

• [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].

  Casopis lekaru ceskych 20040101

• [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

  Srpski arhiv za celokupno lekarstvo 20040101

• [The multidrug tumor cell resistance phenotype caused by the impaired cell death program].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20040101

• Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes.

  Brain tumor pathology 20040101

• [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].

  Voprosy onkologii 20040101

• Treatment options in hormone-refractory metastatic prostate carcinoma.

  Tumori 20040101

• Mitoxantrone (Novantrone) in multiple sclerosis: new insights.

  Expert review of neurotherapeutics 20040101

• Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.

  Journal of medicinal chemistry 20031218

• 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031215

• Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031215

• Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.

  International journal of cancer 20031210

• Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.

  International journal of cancer 20031210

• High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.

  Annals of hematology 20031201

• Stem cell transplantation for multiple sclerosis: what is the evidence?

  Blood reviews 20031201

• Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).

  Annals of oncology : official journal of the European Society for Medical Oncology 20031201

• Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.

  British journal of haematology 20031201

• Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.

  Cancer 20031201

• Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.

  Molecular pharmacology 20031201

• Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

  Bone marrow transplantation 20031201

• Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.

  BioTechniques 20031201

• Chloroma of the orbit in a non-leukemic adult: A case report.

  Orbit (Amsterdam, Netherlands) 20031201

• MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.

  International journal of hematology 20031201

• High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis.

  Journal of hematotherapy & stem cell research 20031201

• [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].

  Revue neurologique 20031201

• [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20031201

• Highlights from the XII European Cancer Conference Copenhagen, Denmark.

  Clinical prostate cancer 20031201

• New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).

  Journal of experimental & clinical cancer research : CR 20031201

• The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Neurology 20031125

• Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.

  British journal of cancer 20031117

• P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

  British journal of cancer 20031103

• Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.

  British journal of cancer 20031103

• Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

  Annals of hematology 20031101

• Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis.

  Journal of cardiovascular pharmacology 20031101

• Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.

  Leukemia 20031101

• Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.

  Gynecologic oncology 20031101

• The role of breast cancer resistance protein in acute lymphoblastic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

• Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

  Molecular cancer therapeutics 20031101

• [Chemotherapy of hormone refractory prostate carcinoma].

  Der Urologe. Ausg. A 20031101

• Synthesis and characterization of the tumor targeting mitoxantrone-insulin conjugate.

  Archives of pharmacal research 20031101

• Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.

  European journal of haematology 20031101

• Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20031101

• Clinical use of rituximab in haematological malignancies.

  British journal of cancer 20031020

• Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.

  British journal of cancer 20031020

• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).

  Oncogene 20031020

• Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour.

  British journal of cancer 20031006

• Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents.

  Biochemical pharmacology 20031001

• [Mitoxanthrone in the therapy of multiple sclerosis].

  Der Nervenarzt 20031001

• What next after hormonotherapy in cancer prostate?

  Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20031001

• Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915

• Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

  British journal of cancer 20030915

• Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

  British journal of cancer 20030915

• Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2'-deoxyuridine (RP101).

  Cancer research 20030915

• Breast cancer resistance protein exports sulfated estrogens but not free estrogens.

  Molecular pharmacology 20030901

• New and emerging treatment options for multiple sclerosis.

  The Lancet. Neurology 20030901

• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030901

• Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation.

  Biochemical pharmacology 20030901

• The effect of mitoxantrone on anti-pig immunization in baboons.

  Xenotransplantation 20030901

• Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.

  Journal of clinical pharmacology 20030901

• [Analysis of prognostic factors in patients with refractory acute myeloid leukemia].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20030901

• Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

  Cancer research 20030901

• Extramedullary acute myeloid leukemia (granulocytic sarcoma) with arm paresis, maculopapular exanthema and organ involvement.

  Leukemia & lymphoma 20030901

• Non-Hodgkin's lymphoma presenting as a giant chest wall mass.

  Leukemia & lymphoma 20030901

• Rituximab in heavily pretreated cutaneous B-cell lymphoma.

  Leukemia & lymphoma 20030901

• Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL.

  Hematological oncology 20030901

• Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer.

  Journal of controlled release : official journal of the Controlled Release Society 20030828

• Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.

  Blood 20030815

• A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

  The Biochemical journal 20030801

• Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.

  Molecular pharmacology 20030801

• Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

• Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.

  Leukemia 20030801

• Expression and functional analyses of breast cancer resistance protein in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Therapy-related leukemia in mitozantrone treated patients.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030801

• Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

  Haematologica 20030801

• [Interferon beta treatment in multiple sclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20030801

• [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].

  Nihon rinsho. Japanese journal of clinical medicine 20030801

• [Immunologic therapy for secondary and primary progressive multiple sclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20030801

• Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.

  Onkologie 20030801

• Oxidation of mitoxantrone by lactoperoxidase.

  Biochimica et biophysica acta 20030730

• Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone.

  Journal of medicinal chemistry 20030717

• Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

  Blood 20030715

• Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

  Blood 20030715

• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  Cancer research 20030715

• Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.

  British journal of cancer 20030707

• Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?

  British journal of cancer 20030707

• Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.

  Cancer chemotherapy and pharmacology 20030701

• Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.

  Surgical oncology clinics of North America 20030701

• Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.

  British journal of cancer 20030616

• Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment.

  Alimentary pharmacology & therapeutics 20030615

• Chemotherapy of prostate cancer: present and future.

  Current urology reports 20030601

• Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.

  Leukemia 20030601

• Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.

  Leukemia 20030601

• Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin.

  Therapeutic drug monitoring 20030601

• High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.

  Cancer 20030601

• Therapy-related acute promyelocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• Current strategies in the management of hormone refractory prostate cancer.

  Cancer treatment reviews 20030601

• The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  Urology 20030601

• First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.

  Clinical lymphoma 20030601

• The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia.

  Leukemia & lymphoma 20030601

• Multiple paradigm shifts in multiple sclerosis.

  Current opinion in neurology 20030601

• Current disease-modifying therapies in multiple sclerosis.

  Seminars in neurology 20030601

• Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy.

  Clinical prostate cancer 20030601

• Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991-2001).

  Veterinary and comparative oncology 20030601

• [Diagnosis and treatment of multiple sclerosis. Update, 2003].

  MMW Fortschritte der Medizin 20030526

• CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.

  Blood 20030515

• Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515

• Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?

  Leukemia research 20030501

• The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

  International journal of oncology 20030501

• Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.

  The Journal of urology 20030501

• Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo.

  Cancer chemotherapy and pharmacology 20030501

• Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.

  The Annals of pharmacotherapy 20030501

• Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.

  Cancer 20030501

• Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer.

  Annals of surgical oncology 20030501

• A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

  Leukemia 20030501

• Electrochemical determination of interaction parameters for DNA and mitoxantrone in an irreversible redox process.

  Biophysical chemistry 20030501

• Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

  Neurology 20030422

• Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

  Leukemia research 20030401

• De-intercalation of ethidium bromide and acridine orange by xanthine derivatives and their modulatory effect on anticancer agents: a study of DNA-directed toxicity enlightened by time correlated single photon counting.

  Journal of biomolecular structure & dynamics 20030401

• Relevance of drug uptake, cellular distribution and cell membrane fluidity to the enhanced sensitivity of Down's syndrome fibroblasts to anticancer antibiotic-mitoxantrone.

  Biochimica et biophysica acta 20030401

• [Mitoxantrone, a new reality].

  Revista de neurologia 20030401

• Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.

  American journal of hematology 20030401

• Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

  Journal of neurosurgery 20030401

• [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].

  Ai zheng = Aizheng = Chinese journal of cancer 20030401

• FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.

  Annals of hematology 20030401

• Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.

  Cancer chemotherapy and pharmacology 20030401

• A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20030401

• Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion.

  Onkologie 20030401

• [99mTc-MIBI myocardial perfusion tomography for monitoring the anthracycline cardiotoxicity].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20030401

• Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.

  Journal of drug targeting 20030401

• Mitoxantrone trial in multiple sclerosis.

  Lancet (London, England) 20030329

• Investigation on the interaction of DNA and electroactive ligands using a rapid electrochemical method.

  Journal of biochemical and biophysical methods 20030328

• Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours.

  British journal of cancer 20030324

• A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.

  Blood 20030315

• Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

  Cancer research 20030315

• Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.

  Journal of medicinal chemistry 20030313

• Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.

  British journal of cancer 20030310

• Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells.

  International journal of cancer 20030301

• [Adjuvant and additive therapy for cancer of the pancreas].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20030301

• Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells.

  Human gene therapy 20030301

• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

  Cancer cell 20030301

• Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030301

• [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].

  Vnitrni lekarstvi 20030301

• Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.

  British journal of cancer 20030224

• Synthesis and biological evaluation of 2,7-Dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione derivatives, a novel group of anticancer agents active on a multidrug resistant cell line.

  Bioorganic & medicinal chemistry 20030220

• Mitoxantrone in progressive multiple sclerosis: when and how to treat?

  Journal of the neurological sciences 20030215

• Interferon beta-1a in primary progressive multiple sclerosis.

  Journal of the neurological sciences 20030215

• Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature.

  American journal of hematology 20030201

• A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030201

• Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation.

  The Journal of thoracic and cardiovascular surgery 20030201

• Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.

  BJU international 20030201

• Relevance network between chemosensitivity and transcriptome in human hepatoma cells.

  Molecular cancer therapeutics 20030201

• Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.

  Annals of hematology 20030201

• Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030201

• Severe heart failure in a young multiple sclerosis patient.

  Journal of neurology 20030201

• Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.

  Journal of neurology 20030201

• Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

  Seminars in oncology 20030201

• Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate.

  The Journal of steroid biochemistry and molecular biology 20030201

• A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer.

  Chang Gung medical journal 20030201

• A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.

  Clinical therapeutics 20030201

• Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

  British journal of cancer 20030127

• Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

  Blood 20030101

• Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

  International journal of cancer 20030101

• Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones.

  Mutagenesis 20030101

• Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

  Molecular pharmacology 20030101

• Recent advances in pediatric acute lymphoblastic and myeloid leukemia.

  Current opinion in oncology 20030101

• Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.

  Cancer 20030101

• NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.

  Cancer research 20030101

• Chemosensitivity testing as an aid to anti-cancer drug and regimen development.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20030101

• ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20030101

• Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.

  Molecular cancer therapeutics 20030101

• Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.

  Urologia internationalis 20030101

• Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?

  Clinical neuropharmacology 20030101

• The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dihydrate in human neutrophils.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030101

• Multiple sclerosis. Treatment is shifting.

  Mayo Clinic health letter (English ed.) 20030101

• C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

  Breast cancer research : BCR 20030101

• Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

  European neurology 20030101

• Skin metastasis from prostate adenocarcinoma.

  Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20030101

• A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20030101

• [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].

  Klinische Padiatrie 20030101

• High-risk localized prostate cancer: primary surgery and adjuvant therapy.

  Urologic oncology 20030101

• Regional celiac artery infusion in the adjuvant treatment of pancreatic cancer.

  Anticancer research 20030101

• [Mitoxantrone].

  Neurologia (Barcelona, Spain) 20030101

• New principles in the treatment of prostate cancer--the oncologist's view.

  Scandinavian journal of urology and nephrology. Supplementum 20030101

• Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

  BMC cancer 20030101

• Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

  Cancer biology & therapy 20030101

• Mitoxantrone: a hypomethylating agent?

  Cancer biology & therapy 20030101

• Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.

  Anticancer research 20030101

• Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosis.

  ACP journal club 20030101

• DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.

  Cell cycle (Georgetown, Tex.) 20030101

• Ifosfamide in hematological malignancies of adults.

  Oncology 20030101

• Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).

  Health and quality of life outcomes 20030101

• Surrogate end points of quality of life assessment: have we really found what we are looking for?

  Health and quality of life outcomes 20030101

• First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer.

  Anticancer research 20030101

• The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.

  Cellular & molecular biology letters 20030101

• Immunosuppressive antimetabolites inhibit induction of contact hypersensitivity while lymphoablative drugs also prevent its expression.

  European journal of dermatology : EJD 20030101

• High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.

  Tumori 20030101

• Docetaxel for the treatment of hormone-refractory prostate cancer.

  Reviews in urology 20030101

• Docetaxel for the treatment of hormone-refractory prostate cancer.

  Reviews in urology 20030101

• Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

  Blood 20021215

• Low levels of ABCG2 expression in adult AML blast samples.

  Blood 20021215

• An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.

  Cancer 20021215

• Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.

  The Journal of biological chemistry 20021213

• ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

  Biochemical and biophysical research communications 20021213

• Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation.

  British journal of cancer 20021202

• Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.

  Blood 20021201

• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

  The Journal of urology 20021201

• Editorial: States and state transitions are all that really matter.

  The Journal of urology 20021201

• Issues and practices in multiple sclerosis.

  Neurorehabilitation and neural repair 20021201

• Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.

  British journal of haematology 20021201

• Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.

  Bone marrow transplantation 20021201

• Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.

  American journal of clinical oncology 20021201

• [Immunosuppressive medication in multiple sclerosis].

  Revista de neurologia 20021201

• Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  Lancet (London, England) 20021201

• Synthesis of symmetrical 1,5-bisacyloxyanthraquinone derivatives and their dual activity of cytotoxicity and lipid peroxidation.

  Archiv der Pharmazie 20021201

• Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.

  Leukemia & lymphoma 20021201

• Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.

  Internal medicine journal 20021101

• A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.

  Haematologica 20021101

• Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Synthesis of symmetrical 1,5-bis-thio-substituted anthraquinones for cytotoxicity in cultured tumor cells and lipid peroxidation.

  Chemical & pharmaceutical bulletin 20021101

• Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).

  Journal of pediatric hematology/oncology 20021101

• Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

  Journal of neurosurgery 20021101

• High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.

  Journal of cancer research and clinical oncology 20021101

• Rituximab therapy for indolent non-Hodgkin's lymphoma.

  Anti-cancer drugs 20021101

• Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.

  Transplantation 20021027

• [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

  Deutsche medizinische Wochenschrift (1946) 20021025

• Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.

  British journal of cancer 20021021

• Inhibition of basal and transforming growth factor-beta-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts.

  The Journal of biological chemistry 20021011

• A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis.

  British journal of cancer 20021007

• Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy.

  Acta neurologica Scandinavica 20021001

• Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

  Blood 20021001

• Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

  Blood 20021001

• Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20021001

• A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20021001

• Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.

  Current protein & peptide science 20021001

• CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.

  American journal of clinical oncology 20021001

• Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.

  International journal of hematology 20021001

• Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.

  Annals of hematology 20021001

• Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

  Gynecologic oncology 20021001

• Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

  Neurology 20020924

• Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

  Neurology 20020924

• Key issues in the diagnosis and treatment of multiple sclerosis. An overview.

  Neurology 20020924

• Weekly epirubicin in patients with hormone-resistant prostate cancer.

  British journal of cancer 20020923

• Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.

  Biochimica et biophysica acta 20020920

• DNA topoisomerase I and II expression in drug resistant germ cell tumours.

  British journal of cancer 20020909

• Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.

  British journal of cancer 20020909

• Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

  European journal of cancer (Oxford, England : 1990) 20020901

• Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.

  Blood 20020901

• Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.

  British journal of haematology 20020901

• Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

  Cancer research 20020901

• Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.

  Haematologica 20020901

• Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

  Haematologica 20020901

• Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.

  American journal of hematology 20020901

• Chemotherapy for prostate cancer.

  Urology 20020901

• Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia.

  Annals of hematology 20020901

• Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.

  Annals of hematology 20020901

• A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.

  Anti-cancer drugs 20020901

• Updated meta analysis finds that interferon-alpha improves progression-free and overall survival in low-grade non-Hodgkin's lymphoma when administered with chemotherapy that contains anthracycline or mitoxantrone.

  Clinical lymphoma 20020901

• Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.

  Clinical lymphoma 20020901

• Approved and future pharmacotherapy for multiple sclerosis.

  The neurologist 20020901

• Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.

  The Journal of biological chemistry 20020830

• Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.

  International journal of radiation oncology, biology, physics 20020801

• Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen.

  The Journal of urology 20020801

• Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.

  The Journal of urology 20020801

• BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.

  Leukemia 20020801

• Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.

  Haematologica 20020801

• Chemotherapy for androgen-independent prostate cancer.

  Seminars in urologic oncology 20020801

• A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.

  Journal of neuro-oncology 20020801

• Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma.

  Annals of hematology 20020801

• [Immunosuppressants and multiple sclerosis].

  Revista de neurologia 20020801

• Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.

  Leukemia & lymphoma 20020801

• Autologous stem cell transplants in treatment of multiple sclerosis: where we stand and future prospects.

  International journal of hematology 20020801

• Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

  Cancer gene therapy 20020701

• A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

  British journal of cancer 20020701

• Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.

  British journal of cancer 20020701

• Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia.

  British journal of haematology 20020701

• Monitoring, and estimation of kinetic data, by piezoelectric impedance analysis, of the binding of the anticancer drug mitoxantrone to surface-immobilized DNA.

  Analytical and bioanalytical chemistry 20020701

• Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.

  American journal of hematology 20020701

• Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.

  International journal of cancer 20020701

• beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

  Experimental hematology 20020701

• Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.

  Journal of cancer research and clinical oncology 20020701

• Quantitative analysis of mitoxantrone by surface-enhanced resonance Raman scattering.

  Analytical chemistry 20020701

• Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.

  European journal of haematology 20020701

• Conjunctival chloroma (granulocytic sarcoma).

  Lancet (London, England) 20020629

• A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.

  Biochemistry 20020625

• [Experience with fludarabine treatment and review of the literature].

  Orvosi hetilap 20020616

• Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020615

• Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents.

  Journal of medicinal chemistry 20020606

• High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.

  British journal of cancer 20020605

• Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.

  Bioorganic & medicinal chemistry letters 20020603

• High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).

  Leukemia research 20020601

• In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.

  British journal of haematology 20020601

• Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

  Anti-cancer drugs 20020601

• Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.

  Current urology reports 20020601

• Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.

  International journal of hematology 20020601

• Flow cytometric analysis of breast cancer resistance protein expression and function.

  Cytometry 20020601

• Chloroma (aleukaemic leukaemia cutis) initially diagnosed as cutaneous lymphoma.

  Clinical and experimental dermatology 20020601

• Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.

  Clinical lymphoma 20020601

• Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.

  Clinical lymphoma 20020601

• Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.

  European journal of haematology 20020601

• Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.

  The Netherlands journal of medicine 20020601

• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  Molecular cancer therapeutics 20020601

• [Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics].

  Yao xue xue bao = Acta pharmaceutica Sinica 20020601

• Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

  Blood 20020515

• Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone.

  The American journal of cardiology 20020515

• Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020515

• Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

  British journal of cancer 20020506

• Occupational asthma due to mitoxantrone.

  Allergy 20020501

• Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.

  Cancer chemotherapy and pharmacology 20020501

• Decrease in heart ventricular ejection fraction during multiple sclerosis.

  European journal of neurology 20020501

• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.

  Leukemia 20020501

• Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.

  Haematologica 20020501

• Abietane diterpenoids from Coleus xanthanthus.

  Journal of natural products 20020501

• Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

  Cancer chemotherapy and pharmacology 20020501

• Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

  Leukemia & lymphoma 20020501

• Considerations in the treatment of relapsing-remitting multiple sclerosis.

  Neurology 20020423

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415

• Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone.

  American journal of hematology 20020401

• 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.

  Genes, chromosomes & cancer 20020401

• Anthracyclines in the treatment of gynecologic malignancies.

  Gynecologic oncology 20020401

• Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.

  Cancer research 20020401

• Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20020401

• The role of mitoxantrone in non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20020401

• The role of drug efflux pumps in acute myeloid leukemia.

  Leukemia & lymphoma 20020401

• CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.

  Leukemia & lymphoma 20020401

• A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.

  Bone marrow transplantation 20020401

• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  Molecular cancer therapeutics 20020401

• European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.

  Cancer 20020315

• Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.

  Cytokine 20020307

• Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.

  British journal of cancer 20020304

• Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

  Leukemia research 20020301

• CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20020301

• Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes.

  Biochemical pharmacology 20020301

• Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

  Japanese journal of cancer research : Gann 20020301

• Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.

  Clinical lymphoma 20020301

• Study of therapy resistance in cancer cells with functional proteome analysis.

  Clinical chemistry and laboratory medicine 20020301

• Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.

  European journal of haematology 20020301

• Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the 'ABCNR' drugs in multiple sclerosis.

  Seminars in neurology 20020301

• Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.

  International journal of cancer 20020220

• The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine.

  Biochemical pharmacology 20020215

• The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents. Part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone.

  Biochemical pharmacology 20020215

• CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours.

  British journal of cancer 20020212

• Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

  British journal of cancer 20020212

• Chemotherapeutic stress mediated by certain antitumor antibiotics induces an atypical CD69+ surface phenotype in peripheral T-lymphocytes.

  International immunopharmacology 20020201

• Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020201

• A prolonged APTT in a patient with a low grade malignant NHL - a case report.

  Haematologica 20020201

• BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.

  Bone marrow transplantation 20020201

• Hematopoietic cell transplantation beyond first remission.

  Leukemia 20020201

• Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.

  Seminars in oncology 20020201

• Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

  Cancer 20020201

• Therapeutic approaches to secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20020201

• [Value of mitoxantrone in metastatic hormone-resistant prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20020201

• [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20020201

• Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.

  Leukemia & lymphoma 20020201

• Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.

  Leukemia & lymphoma 20020201

• Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

  European journal of haematology 20020201

• Acute lymphocytic leukemia CNS disease presenting as central diabetes insipidus.

  The Journal of the Association of Physicians of India 20020201

• Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.

  Journal of neuro-oncology 20020201

• Chronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment.

  Hematology (Amsterdam, Netherlands) 20020201

• Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer.

  Breast (Edinburgh, Scotland) 20020201

• 2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents.

  Journal of medicinal chemistry 20020131

• Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

  Neurology 20020122

• In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.

  Cancer research 20020115

• A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.

  International journal of cancer 20020110

• PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.

  Oncogene 20020110

• c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells.

  Leukemia research 20020101

• Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.

  Blood 20020101

• Effects of cytarabine and various anthracyclins on platelet activation: characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia.

  International journal of cancer 20020101

• Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

  Haematologica 20020101

• The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• Controversies in chemotherapy of prostate cancer.

  Frontiers of radiation therapy and oncology 20020101

• Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.

  International journal of hematology 20020101

• Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.

  Cancer investigation 20020101

• Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens.

  Breast cancer research and treatment 20020101

• Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.

  Clinical breast cancer 20020101

• Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.

  Leukemia & lymphoma 20020101

• Synthesis and cytotoxicity of 9-alkoxy-1,5-dichloroanthracene derivatives in murine and human cultured tumor cells.

  Archiv der Pharmazie 20020101

• Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.

  Tumori 20020101

• Treatment of elderly Hodgkin's lymphoma patients. The experience of the Italian Lymphoma Intergroup.

  Tumori 20020101

• The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.

  Anticancer research 20020101

• Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.

  BMC cancer 20020101

• Differentiation of multiple sclerosis subtypes: implications for treatment.

  CNS drugs 20020101

• Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

  CNS drugs 20020101

• [Thermodynamic analysis of interaction of mitoxantrone with deoxytetranucleotide 5'-d(TpGpCpA) in the water solution based on 1H-NMR spectrophotometry].

  Biofizika 20020101

• ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020101

• Binding free energy of selected anticancer compounds to DNA--theoretical calculations.

  Journal of molecular modeling 20020101

• Lactic acid based PEU/HA and PEU/BCP composites: Dynamic mechanical characterization of hydrolysis.

  Journal of biomedical materials research 20020101

• A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone.

  Acta biochimica Polonica 20020101

• Inv(4)(p14q27) in a case with de novo acute nonlymphocytic leukemia.

  Acta haematologica 20020101

• CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.

  Acta haematologica 20020101

• The antineoplastic treatment in the elderly.

  La Clinica terapeutica 20020101

• [Effect of intercalators on the properties of liquid-crystalline dispersions of nucleic acid-chitosan complex].

  Molekuliarnaia biologiia 20020101

• Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype.

  Anticancer research 20020101

• [Post-marketing surveillance information transmitted via electronic mail in a University Hospital].

  Therapie 20020101

• Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.

  Oncology 20020101

• Conference synopsis: hematopoietic stem cell therapy in autoimmune diseases, October 2001.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20020101

• A long-term survival case underwent repeated hepatic arterial infusion chemotherapy with portal branch ligation and wrapping of the liver using sheets for hepatocellular carcinoma.

  Hepato-gastroenterology 20020101

• Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.

  Haematologia 20020101

• Providing pharmaceutical care to the multiple sclerosis patient.

  Journal of the American Pharmaceutical Association (Washington,D.C. : 1996) 20020101

• Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine.

  The hematology journal : the official journal of the European Haematology Association 20020101

• P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs.

  Journal of experimental therapeutics & oncology 20020101

• NTPase/helicase of Flaviviridae: inhibitors and inhibition of the enzyme.

  Acta biochimica Polonica 20020101

• Loss of growth factor sensitivity and development of mitoxantrone resistance in transplanted recurrent SA7HD myeloid leukemia.

  Journal of experimental therapeutics & oncology 20020101

• Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.

  Veterinary therapeutics : research in applied veterinary medicine 20020101

• Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  Cancer investigation 20020101

• Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.

  Molecular cancer therapeutics 20020101

• The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.

  Neoplasma 20020101

• Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.

  Blood 20011215

• Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.

  European journal of cancer (Oxford, England : 1990) 20011201

• Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma.

  Melanoma research 20011201

• Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.

  Cancer research 20011201

• A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

  Leukemia 20011201

• Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.

  Cancer 20011201

• Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.

  American journal of hematology 20011201

• Contemporary immunomodulatory therapy for multiple sclerosis.

  Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20011201

• [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].

  Bulletin du cancer 20011201

• The role of half-transporters in multidrug resistance.

  Journal of bioenergetics and biomembranes 20011201

• [Superficial bladder neoplasia unresponsive to endocavitary treatment: when should the treatment approach be changed?].

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20011201

• A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.

  Acta neurologica Belgica 20011201

• Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.

  Journal of pediatric hematology/oncology 20011201

• [Recent therapeutic strategy for multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20011201

• Separation methods for anthraquinone related anti-cancer drugs.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.

  Cancer 20011115

• Recent advances in the prevention of anthracycline cardiotoxicity in childhood.

  Current medicinal chemistry 20011101

• Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.

  Gynecologic oncology 20011101

• Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.

  British journal of haematology 20011101

• A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.

  Japanese journal of clinical oncology 20011101

• Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.

  Bone marrow transplantation 20011101

• Primary progressive multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20011101

• Palliative care in patients with multiple sclerosis.

  Neurologic clinics 20011101

• DNA interaction and cytotoxicity of a new series of indolo[2,3-b]quinoxaline and pyridopyrazino[2,3-b]indole derivatives.

  Chemico-biological interactions 20011025

• Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

  Blood 20011015

• Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.

  Cancer 20011015

• Hydrogels for combination delivery of antineoplastic agents.

  Biomaterials 20011001

• Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

  Leukemia 20011001

• In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

  Leukemia 20011001

• Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

  Leukemia 20011001

• Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.

  Anti-cancer drugs 20011001

• Studies on anthracenes. 3. Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives.

  Chemical & pharmaceutical bulletin 20011001

• Studies on anthracenes. 2. Synthesis and cytotoxic evaluation of 9-acyloxy 1,8-dichloroanthracene derivatives.

  Chemical & pharmaceutical bulletin 20011001

• [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Nonsurgical treatment of hepatocellular carcinoma.

  Seminars in oncology 20011001

• Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20011001

• Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.

  Bone marrow transplantation 20011001

• The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.

  Cancer chemotherapy and pharmacology 20011001

• Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011001

• FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20011001

• Intracavitary therapies for mesothelioma.

  Current treatment options in oncology 20011001

• Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

  Blood 20010915

• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  Cancer research 20010915

• University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010915

• [New approaches in research of therapy of multiple sclerosis].

  Medizinische Klinik (Munich, Germany : 1983) 20010915

• Poor prognosis acute myelogenous leukemia: 3--biological and molecular biological changes during remission induction therapy.

  Leukemia research 20010901

• Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

  Blood 20010901

• Cost-effectiveness analysis with risk aversion.

  Health economics 20010901

• Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone.

  American journal of veterinary research 20010901

• Detection of bcl-2/IgH rearrangements by quantitative-competitive PCR and capillary electrophoresis.

  Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology 20010901

• Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.

  Japanese journal of cancer research : Gann 20010901

• Prostate cancer in the older man.

  Oncology (Williston Park, N.Y.) 20010901

• [Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].

  Vnitrni lekarstvi 20010901

• [Treatment of progressive forms of multiple sclerosis].

  Revue neurologique 20010901

• Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20010901

• Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone.

  FEBS letters 20010817

• Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

  International journal of cancer 20010815

• A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

  Blood 20010815

• A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

  Cancer research 20010815

• The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.

  Mechanisms of ageing and development 20010801

• Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

  Blood 20010801

• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  Blood 20010801

• CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.

  American journal of clinical oncology 20010801

• Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).

  American journal of clinical oncology 20010801

• Anthracycline-induced cardiomyopathy.

  Seminars in oncology 20010801

• Treatment of hormone refractory prostate cancer.

  Seminars in urologic oncology 20010801

• Can chemotherapy alter the course of prostate cancer?

  Seminars in urologic oncology 20010801

• Complications of chemotherapy for prostate cancer.

  Seminars in urologic oncology 20010801

• Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

  Onkologie 20010801

• Perioperative locoregional application of mitoxantrone in patients with early breast carcinoma.

  Journal of chemotherapy (Florence, Italy) 20010801

• Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom.

  Leukemia & lymphoma 20010801

• Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.

  Leukemia & lymphoma 20010801

• Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.

  Prescrire international 20010801

• Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.

  Journal of neuro-oncology 20010801

• Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.

  Cancer research 20010715

• Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.

  Biochemical and biophysical research communications 20010706

• Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.

  American journal of hematology 20010701

• Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.

  International journal of radiation oncology, biology, physics 20010701

• Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.

  European journal of haematology. Supplementum 20010701

• Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.

  European journal of haematology. Supplementum 20010701

• Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.

  Annals of hematology 20010701

• Incremental net benefit in randomized clinical trials.

  Statistics in medicine 20010615

• A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

  Biochimica et biophysica acta 20010606

• Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.

  Bioorganic & medicinal chemistry letters 20010604

• Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

  European journal of cancer (Oxford, England : 1990) 20010601

• Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.

  Leukemia 20010601

• The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.

  Leukemia 20010601

• Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.

  Leukemia 20010601

• [Chemotherapy in gastroenterologic neuroendocrine tumors].

  Recenti progressi in medicina 20010601

• Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.

  Annals of hematology 20010601

• A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010601

• Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010601

• Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.

  Journal of experimental & clinical cancer research : CR 20010601

• From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

  Cellular and molecular life sciences : CMLS 20010601

• Paclitaxel and docetaxel in prostate cancer.

  Hematology/oncology clinics of North America 20010601

• Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.

  Blood 20010515

• Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides.

  The Journal of biological chemistry 20010511

• Atp-bound topoisomerase ii as a target for antitumor drugs.

  The Journal of biological chemistry 20010511

• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501

• Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.

  Leukemia 20010501

• In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.

  Haematologica 20010501

• Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.

  Haematologica 20010501

• Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study.

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20010501

• Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.

  Bone marrow transplantation 20010501

• Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone.

  Neoplasia (New York, N.Y.) 20010501

• Immunologic therapy for relapsing-remitting multiple sclerosis.

  Current neurology and neuroscience reports 20010501

• Immunologic therapy for secondary and primary progressive multiple sclerosis.

  Current neurology and neuroscience reports 20010501

• HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?

  International journal of oncology 20010401

• Complications associated with intraperitoneal chemotherapy catheters.

  Gynecologic oncology 20010401

• Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.

  Cancer research 20010401

• Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.

  American journal of clinical oncology 20010401

• Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.

  Expert opinion on pharmacotherapy 20010401

• High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.

  Bone marrow transplantation 20010401

• High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.

  Leukemia & lymphoma 20010401

• Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.

  Annals of hematology 20010401

• Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.

  Bone marrow transplantation 20010401

• HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.

  Bone marrow transplantation 20010401

• Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.

  Haematologica 20010301

• Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.

  British journal of cancer 20010301

• Primary low-grade B cell non-Hodgkin's lymphoma of MALT type simultaneously arising in the colon and in the lung: report of a case.

  Diseases of the colon and rectum 20010301

• Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  Anti-cancer drugs 20010301

• Neutrophilic eccrine hidradenitis in two neutropaenic patients.

  Clinical and experimental dermatology 20010301

• Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.

  Annals of hematology 20010301

• Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.

  Cancer gene therapy 20010301

• Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.

  Leukemia & lymphoma 20010301

• Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20010301

• Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

  European journal of haematology 20010301

• Heterogeneity of proteinkinase C activity and PKC-zeta expression in clinical breast carcinomas.

  Clinical and experimental medicine 20010301

• Secondary leukemia after adjuvant chemotherapy for breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

  Biochemical and biophysical research communications 20010209

• Anthracycline adjuvant chemotherapy: how much is enough?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

  The Journal of pharmacology and experimental therapeutics 20010201

• Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.

  Gynecologic oncology 20010201

• A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.

  Critical reviews in oncology/hematology 20010201

• Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.

  Cancer 20010201

• [Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].

  Revista espanola de medicina nuclear 20010201

• Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.

  European urology 20010201

• Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.

  American journal of clinical oncology 20010201

• High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.

  Leukemia 20010201

• Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.

  Hematology/oncology clinics of North America 20010201

• [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].

  Der Nervenarzt 20010201

• Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.

  Bone marrow transplantation 20010201

• Docetaxel in prostate cancer.

  Anti-cancer drugs 20010201

• Multiple sclerosis treatment 2001.

  Neurologic clinics 20010201

• [Conjugation of mitoxantrone-loaded nanospheres and anti-C-erbB-2 monoclonal antibodies].

  Yao xue xue bao = Acta pharmaceutica Sinica 20010201

• Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.

  Bioorganic & medicinal chemistry letters 20010108

• Chemotherapy and marrow transplantation for congenital leukaemia.

  Archives of disease in childhood. Fetal and neonatal edition 20010101

• DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.

  Molecular pharmacology 20010101

• The role of laparoscopy in second-look evaluations for ovarian cancer.

  Gynecologic oncology 20010101

• Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.

  British journal of cancer 20010101

• Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.

  British journal of haematology 20010101

• DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.

  Chemical research in toxicology 20010101

• Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features.

  Human pathology 20010101

• 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.

  Breast cancer (Tokyo, Japan) 20010101

• Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin.

  Bone marrow transplantation 20010101

• Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.

  Cancer chemotherapy and pharmacology 20010101

• High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.

  Bone marrow transplantation 20010101

• Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer.

  Journal of the American Animal Hospital Association 20010101

• Applications of microarray technology in breast cancer research.

  Breast cancer research : BCR 20010101

• Progressing prostate carcinoma.

  The oncologist 20010101

• The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.

  European journal of gynaecological oncology 20010101

• Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.

  Cancer investigation 20010101

• Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis.

  Hepato-gastroenterology 20010101

• Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.

  Journal of cancer research and clinical oncology 20010101

• Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.

  American journal of hematology 20010101

• Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.

  Leukemia & lymphoma 20010101

• Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20010101

• A systematic overview of chemotherapy effects in acute myeloid leukaemia.

  Acta oncologica (Stockholm, Sweden) 20010101

• Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.

  Advances in therapy 20010101

• Cytotoxicity evaluation of natural coptisine and synthesis of coptisine from berberine.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer.

  Oncology reports 20010101

• Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cells.

  Tumori 20010101

• [Improved treatment results in children with AML: Results of study AML-BFM 93].

  Klinische Padiatrie 20010101

• Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.

  Neoplasma 20010101

• On the probability of cost-effectiveness using data from randomized clinical trials.

  BMC medical research methodology 20010101

• T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.

  Oncology 20010101

• pH and chemotherapy.

  Novartis Foundation symposium 20010101

• DNA-damage signaling and apoptosis.

  Genome biology 20010101

• Treatment options in hormone-refractory prostate cancer: current and future approaches.

  Drugs 20010101

• The treatment challenge of hormone-refractory prostate cancer.

  Cancer control : journal of the Moffitt Cancer Center 20010101

• Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.

  Anticancer research 20010101

• [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].

  Neurologia i neurochirurgia polska 20010101

• Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20010101

• Drug helps delay progression of multiple sclerosis.

  FDA consumer 20010101

• Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.

  Tumori 20010101

• Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

  Annals of oncology : official journal of the European Society for Medical Oncology 20000801

• Developing a dynamic pharmacophore model for HIV-1 integrase.

  Journal of medicinal chemistry 20000601

• Sinus bradycardia secondary to mitoxantrone.

  Missouri medicine 20000601

• Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.

  Cancer 20000501

• Sinus bradycardia due to mitoxantrone.

  Southern medical journal 20000401

• Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.

  Cancer chemotherapy and pharmacology 20000101

• First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.

  American journal of clinical oncology 19991201

• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  Cancer research 19991201

• Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone.

  International journal of pharmaceutics 19990415

• Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.

  Seminars in oncology 19980801

• Fas ligand is constitutively secreted by prostate cancer cells in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19980701

• A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.

  Bone marrow transplantation 19971101

• [Mitoxantrone-induced acute left heart failure after intrapleural administration].

  Herz 19970801

• S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.

  Annals of hematology 19970501

• Mitoxantrone-induced bradycardia.

  Annals of internal medicine 19970301

• Pericarditis induced by high-dose cytosine arabinoside chemotherapy.

  Annals of hematology 19970101

• Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency.

  American journal of hematology 19961101

• Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.

  Cancer research 19961015

• Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy.

  American journal of hematology 19960801

• Therapy-related leukemia with a novel 21q22 rearrangement.

  Cancer genetics and cytogenetics 19960801

• [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].

  Bulletin du cancer 19960401

• Expression of inducible nitric oxide synthase in failing and non-failing human heart.

  Journal of molecular and cellular cardiology 19960101

• Comparison of mitozantrone and epirubicin in advanced breast cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 19960101

• Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy.

  Medical oncology (Northwood, London, England) 19951201

• High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19951201

• Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19951101

• [Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 19951101

• Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.

  Journal of medicinal chemistry 19950317

• Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.

  Leukemia 19940401

• Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

  Annals of oncology : official journal of the European Society for Medical Oncology 19940101

• High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.

  Blood 19931115

• Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.

  Leukemia & lymphoma 19931001

• Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19930701

• [Superselective intra-arterial chemotherapy in breast cancer].

  Der Radiologe 19930501

• Inhibitors of human immunodeficiency virus integrase.

  Proceedings of the National Academy of Sciences of the United States of America 19930315

• Bradycardia after rapid intravenous infusin of amphotericin B.

  Lancet (London, England) 19930206

• Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.

  Cancer research 19930201

• A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.

  European journal of cancer (Oxford, England : 1990) 19930101

• Intravesical mitoxantrone in superficial bladder tumours (Ta-T1).

  European journal of cancer (Oxford, England : 1990) 19930101

• Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.

  Investigational new drugs 19930101

• Reversible cardiopathy after accidental overdose of mitoxantrone.

  Pediatric hematology and oncology 19930101

• Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.

  European journal of haematology 19921001

• Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.

  Cancer research 19920715

• [A successful allogeneic bone marrow transplantation for acute promyelocytic leukemia with anthracycline-induced cardiomyopathy at relapse].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 19920401

• Phase II trial of mitoxantrone in head and neck carcinoma.

  American journal of clinical oncology 19910801

• A phase I trial of 14-day continuous intravenous infusion mitoxantrone.

  Anti-cancer drugs 19910601

• Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity.

  Cardiology 19910101

• A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.

  Bone marrow transplantation 19901201

• High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.

  Seminars in oncology 19901201

• [Even mitoxantrone can cause local skin necrosis].

  Lakartidningen 19900117

• An adult case of acute lymphoblastic leukemia with necrotizing leukoencephalopathy.

  Japanese journal of medicine 19900101

• Discoloration of the nails and early anemia after mitoxantrone, folinic acid and 5-fluorouracil.

  Medical oncology and tumor pharmacotherapy 19900101

• Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19890501

• Warning against use of intrathecal mitoxantrone.

  Lancet (London, England) 19890401

• Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines.

  British journal of haematology 19890201

• Salvage of relapsed malignant histiocytosis by autologous bone marrow transplant.

  Bone marrow transplantation 19890101

• [Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].

  Archivos del Instituto de Cardiologia de Mexico 19890101

• Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone.

  Drugs under experimental and clinical research 19890101

• Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.

  Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association 19890101

• Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.

  European journal of cancer & clinical oncology 19880501

• Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study.

  European journal of cancer & clinical oncology 19880301

• Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.

  Cancer treatment reviews 19871201

• Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).

  Investigational new drugs 19871201

• Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.

  Cancer treatment reports 19871201

• A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy.

  The British journal of radiology 19871101

• Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.

  American journal of clinical oncology 19870801

• High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.

  Blood 19870301

• Paraplegia after intrathecal mitozantrone.

  Lancet (London, England) 19861213

• Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy.

  Cancer 19861015

• Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity.

  Oncology 19860101

• Early and delayed clinical cardiotoxicity of doxorubicin.

  Cancer 19850615

• A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).

  Investigational new drugs 19850101

• Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.

  Cancer treatment reports 19830101

• Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats.

  Toxicology letters 19820501